{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2022_00023113", "CSN": null, "TRF": "ORD_1450680_01", "MRN": "48811525", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1191869", "clinicalId": "1193239", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1450680_01", "SampleName": "US1390545.01", "Version": "0", "Sample": {"FM_Id": "ORD_1450680_01", "SampleId": "US1390545.01", "BlockId": "S111-31619B", "TRFNumber": "ORD_1450680_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2022_09_07", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "50", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S111-97891", "MRN": "48811525", "FullName": "\u6797\u6893\u5100", "FirstName": "Tzu_I", "LastName": "Lin", "SubmittedDiagnosis": "Glioblastoma, Cerebellum", "Gender": "Male", "DOB": "1949_08_02", "OrderingMD": "\u8a31\u79c9\u6b0a", "OrderingMDId": "109266", "Pathologist": "\u5468\u5fb7\u76c8", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Brain", "CollDate": "2022_08_16", "ReceivedDate": "2022-09-21 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Diffuse Glioma"}, "PertinentNegatives": {"PertinentNegative": [{"Gene": "EGFR"}, {"Gene": "IDH1"}]}, "Summaries": {"alterationCount": "14", "clinicalTrialCount": "20", "resistiveCount": "1", "sensitizingCount": "3"}, "VariantProperties": {"VariantProperty": [{"geneName": "ERBB2", "isVUS": "true", "variantName": "A270S"}, {"geneName": "MERTK", "isVUS": "true", "variantName": "L514S"}, {"geneName": "MITF", "isVUS": "true", "variantName": "V13A"}, {"geneName": "TSC1", "isVUS": "true", "variantName": "R1062Q"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "FBXW7", "Include": "true", "Alterations": {"Alteration": {"Name": "R465H", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R465H"}}, "Interpretation": "FBXW7 encodes the F_box protein subunit of the SCF ubiquitin ligase complex, which targets proteins for degradation (Welcker and Clurman, 2008; 18094723). FBXW7 inactivation is associated with chromosomal instability and with stabilization of proto_oncogenes, such as mTOR, MYC, cyclin E, NOTCH, and JUN; FBXW7 is therefore considered a tumor suppressor (Akhoondi et al., 2007; 17909001, Welcker and Clurman, 2008; 18094723). Alterations such as seen here may disrupt FBXW7 function or expression (Welcker et al., 2013; 24298052, Welcker et al., 2007; 17298674, Strohmaier et al., 2001; 11565034, Pashkova et al., 2010; 21070969, Akhoondi et al., 2007; 17909001, O Neil et al., 2007; 17646409, Malyukova et al., 2013; 23228967, Thompson et al., 2007; 17646408). FBXW7 mutations have been reported in <2% of glioblastoma samples analyzed in the TCGA datasets (cBio_Brennan et al., 2013; 24120142, Cancer Genome Atlas Research Network., 2008; 18772890). Significant decreases in FBXW7 expression have been reported in more than 80% of glioblastoma samples studied (Hagedorn et al., 2007; 17326833). Lower FBXW7 expression has been reported to be associated with reduced survival in patients with glioblastoma, and may correlate with tumor aggressiveness (Hagedorn et al., 2007; 17326833). FBXW7 loss has been reported to be important for glioma progression by allowing its oncogenic targets to accumulate (Hagedorn et al., 2007; 17326833). FBXW7 inactivating alterations may indicate sensitivity to mTOR inhibitors (Mao et al., 2008; 18787170, Yang et al., 2015; 25749036). Several case studies reported clinical benefit for patients with FBXW7_mutated cancers, including lung adenocarcinoma (Villaruz and Socinski, 2014; 24360397), renal cell carcinoma (Olson et al., 2016; 27079472), and cervical squamous cell carcinoma (Kulkarni et al., 2020; https://doi.org/10.1016/j.ygyno.2020.05.244).", "Include": "true", "ClinicalTrialNote": "Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors.", "Therapies": {"Therapy": [{"Name": null, "GenericName": "Everolimus", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Everolimus is an orally available mTOR inhibitor that is FDA approved to treat renal cell carcinoma (RCC) following antiangiogenic therapy; pancreatic neuroendocrine tumors; and well_differentiated non_functional neuroendocrine tumors of the lung or gastrointestinal tract. Everolimus is also approved to treat either renal angiomyolipoma or subependymal giant cell astrocytoma in association with tuberous sclerosis complex (TSC). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of several case reports describing clinical benefit for patients with FBXW7_mutated cancers treated with mTOR inhibitors, including lung adenocarcinoma (Villaruz and Socinski, 2014; 24360397), renal cell carcinoma (Olson et al., 2016; 27079472), and cervical squamous cell carcinoma (Kulkarni et al., 2020; DOI: 10.1016/j.ygyno.2020.05.244), FBXW7 loss or inactivation may predict sensitivity to everolimus or temsirolimus. </p> <p><b>Supporting Data:</b> A Phase 2 trial of radiotherapy (RT), temozolomide (TMZ), and bevacizumab followed by everolimus and bevacizumab reported that 61% (31/51) of patients with newly diagnosed glioblastoma had objective responses with a median progression_free survival (PFS) of 11.3 months and median overall survival (OS) of 13.9 months (Hainsworth et al., 2012; 22706484). A Phase 2 study of everolimus combined with TMZ and RT for the treatment of newly diagnosed glioblastoma reported a median PFS of 6.4 months and median OS of 15.8 months (Ma et al., 2014; 25526733). A Phase 1 trial of everolimus plus TMZ for patients with newly diagnosed or progressive glioblastoma reported partial responses (PR) in 11% (3/28) and stable disease (SD) in 57% (16/28) of cases (Mason et al., 2011; 22160854). A pilot study of everolimus with gefitinib in patients with recurrent glioblastoma reported 14% (3/22) PRs, 36% (8/22) SDs, and median PFS and OS of 2.6 months and 5.8 months, respectively (Kreisl et al., 2009; 19018475). Everolimus treatment achieved SD in 45% (5/11) of pediatric patients with heavily pretreated low_grade CNS tumors; median PFS of these responses was 14 months (Segal et al., 2016; ISPNO Abstract EPT_21). Whereas frequent adverse events precluded a recommended Phase 2 dose and schedule for the combination of trametinib and everolimus in a Phase 1b trial for solid tumors (Tolcher et al., 2014; 25344362), a retrospective study for heavily pretreated patients with solid tumors reported tolerable regimens of the combination for 23/31 patients, with 16 patients treated >3 months and evaluable patients achieving a median PFS of 6.5 months (Patterson et al., 2018; AACR Abstract 3891). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Temsirolimus", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Temsirolimus is an intravenous mTOR inhibitor that is FDA approved for the treatment of advanced renal cell carcinoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of several case reports describing clinical benefit for patients with FBXW7_mutated cancers treated with mTOR inhibitors, including lung adenocarcinoma (Villaruz and Socinski, 2014; 24360397), renal cell carcinoma (Olson et al., 2016; 27079472), and cervical squamous cell carcinoma (Kulkarni et al., 2020; DOI: 10.1016/j.ygyno.2020.05.244), FBXW7 loss or inactivation may predict sensitivity to everolimus or temsirolimus. </p> <p><b>Supporting Data:</b> A Phase 1, dose_escalation trial combining temsirolimus and radiation/temozolomide therapy, with or without adjuvant temozolomide monotherapy, in patients with newly diagnosed glioblastoma reported no clinical responses but 24/25 patients experienced a period of stable disease; increased infection rates were noted with this regimen (Sarkaria et al., 2010; 20921209). A Phase 1/2 trial of temsirolimus in combination with sorafenib in glioblastoma was terminated at the Phase 2 interim analysis after patients failed to meet the primary endpoint of 6 month progression_free survival; significant toxicity was also observed in the combination therapy, even at low doses of temsirolimus (Lee et al., 2012; 23099651). A Phase 2 study showed that addition of temsirolimus to bevacizumab therapy in patients with recurrent glioblastoma did not add clinical benefit (Lassen et al., 2013; 23564811). A Phase 2 clinical trial of temsirolimus in pediatric glioma reported disease stabilization in 7/17 patients including one patient with anaplastic astrocytoma (Geoerger et al., 2012; 22033322). A Phase 1/2 study of temsirolimus in combination with erlotinib reported 6% (1/16) complete responses, 6% (1/16) partial responses, and 12.5% (2/16) instances of stable disease in patients with anaplastic glioma (Wen et al., 2014; 24470557). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}]}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT03239015", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT05125523", "Include": "true"}, {"nctId": "NCT03158389", "Include": "true"}, {"nctId": "NCT01582191", "Include": "true"}, {"nctId": "NCT03203525", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "MTAP", "Include": "true", "Alterations": {"Alteration": {"Name": "loss", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "loss"}}, "Interpretation": "MTAP encodes S_methyl_5 _thioadenosine (MTA) phosphorylase, a tumor suppressor involved in polyamine metabolism and methionine synthesis, although its enzymatic function is dispensable for its tumor suppressor activity (Limm et al., 2016; 27479139, Tang et al., 2014; 25387827). Decreased expression of MTAP leads to MTA accumulation within tumor cells and their microenvironment (Kirovski et al., 2011; 21356366, Limm et al., 2013; 23265702, Stevens et al., 2009; 19097084), thereby reducing intracellular arginine methylation (Marjon et al., 2016; 27068473, Mavrakis et al., 2016; 26912361, Kryukov et al., 2016; 26912360) and altering cell signaling (Limm et al., 2014; 25087184, Stevens et al., 2009; 19097084). MTAP is located at 9p21, adjacent to CDKN2A and CDKN2B, with which it is frequently co_deleted in various cancers. Other alterations in MTAP are rare and have not been extensively characterized. MTAP loss/homozygous deletion as well as loss of expression has been reported in a wide variety of solid tumors and hematologic cancers (Wei et al., 2016; 27929028, Zhao and Zhao, 2016; 27556634); such events have been correlated with poor prognosis in a variety of cancer types, including hepatocellular carcinoma (Kirovski et al., 2011; 21356366), gastrointestinal stromal tumors (Huang et al., 2009; 19887491), mantle cell lymphoma (MCL)(Marce et al., 2006; 16778103), melanoma (Meyer et al., 2010; 20500769, Wild et al., 2006; 16618867), gastric cancer (Kim et al., 2011; 21412930), myxofibrosarcoma (Li et al., 2014; 25426549), nasopharyngeal carcinoma (He et al., 2015; 26656376), ovarian carcinoma (Wei et al., 2016; 27929028) and non_small cell lung cancer (Su et al., 2014; 24969958). MTAP loss was not prognostic in pediatric B_cell acute lymphocytic leukemia (Mirebeau et al., 2006; 16818274) or in astrocytoma (Becker et al., 2015; 26088413). However, MTAP has also been reported to be overexpressed in colorectal cancer (CRC) samples (Snezhkina et al., 2016; 27433286), and MTAP retention is thought to be important for prostate cancer growth due to continuous supply of SAM (Bistulfi et al., 2016; 26910893). Germline SNPs in MTAP have been correlated with the development of cutaneous melanoma (Antonopoulou et al., 2015; 25407435, Mccioni et al., 2013; 23816148), esophageal cancer (Hyland et al., 2016; 26635288, Lin et al., 2017; 27960044), osteosarcoma (Zhi et al., 2016; 27994653), and CRC (Gu et al., 2013; 23361049). MTAP inactivation produces specific metabolic vulnerabilities that may be sensitive to MAT2A (Kalev et al., 2021; 33450196, Heist et al., 2019; AACR_NCI_EORTC Abstract B116, Marjon et al., 2016; 27068473) or PRMT5 inhibition (Marjon et al., 2016; 27068473, Mavrakis et al., 2016; 26912361, Kryukov et al., 2016; 26912360). A Phase 1 trial of MAT2A inhibitor AG_270 reported 1 PR and 2 SDs lasting longer than 6 months for patients with advanced solid tumors displaying MTAP loss (Heist et al., 2019; AACR_NCI_EORTC Abstract B116). Preclinical data suggest that MTAP loss sensitizes cells to S_adenosyl_L_methionine (SAM)_competitive PRMT5 inhibitors (Guccione and Richard, 2019; 31350521), dual PRMT1 and PRMT5 inhibitors (Fedoriw et al., 2019; 31257072, Srour et al., 2019; 31287990, Gao et al., 2019; 30916320), and PRMT5 inhibitors that selectively bind the PRMT5 when complexed with S_methyl_5 _thioadenosine (MTA), such as MRTX1719, TNG908, and AMG193 (Smith et al., 2022; 35041419, Briggs et al., 2022; AACR Abstract 3941). In preclinical models, MTAP inactivation showed increased sensitivity to inhibitors of purine synthesis or purine analogs, especially upon addition of exogenous MTA (Hansen et al., 2019; 31040154, Tang et al., 2018; 29844120, Munshi et al., 2014; 24928612, de Oliveira et al., 2016; 26751376, Lubin and Lubin, 2009; 19478948, Tang et al., 2012; 22825330, Collins et al., 2012; 22252602, Bertino et al., 2011; 21301207, Coulthard et al., 2011; 21282358, Miyazaki et al., 2007; 17912432, Efferth et al., 2002; 11987241). A Phase 2 study of L_alanosine, an inhibitor of adenine synthesis, as a monotherapy for 65 patients with MTAP_deficient cancers reported no responses and SD for 24% (13/55) of patients (Kindler et al., 2009; 18618081). Preclinical and limited clinical evidence suggest MTAP deficiency may confer sensitivity to pemetrexed (Alhalabi et al., 2022; 35379845).", "Include": "true", "ClinicalTrialNote": "MTAP loss may predict sensitivity to MAT2A inhibitors, or to inhibitors that target PRMT5 when in complex with MTA.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": {"nctId": "NCT05245500", "Include": "true"}}}}, "ReferenceLinks": null}, {"Name": "PDGFRA", "Include": "true", "Alterations": {"Alteration": [{"Name": "D842V", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "D842V"}}, "Interpretation": "PDGFRA encodes platelet_derived growth factor receptor alpha (PDGFR_alpha), a tyrosine kinase receptor that, upon binding of cognate ligands (PDGFA or PDGFB), activates several signaling pathways, including PI3K and MAPK (Andrae et al., 2008; 18483217). PDGFR aberrations, including point mutations, translocations, amplification, and/or overexpression, have been associated with various malignancies (Fletcher, 2004; 15175998). The PDGFRA exon 18 mutation D842V has been characterized as activating and is associated with clinical resistance to imatinib and sunitinib in GISTs (von Mehren et al., 2016; ASCO Abstract 11010, Farag et al., 2016; ASCO Abstract 11011, Cassier et al., 2012; 22718859, Debiec_Rychter et al., 2005; 15685537, Heinrich et al., 2003; 14645423, Heinrich et al., 2008; 18955451, Heinrich et al., 2008; 18955458, Heinrich et al., 2012; 22665524, Heinrich et al., 2012; 22745105, Yoo et al., 2015; 26130666). On the basis of preclinical and preliminary clinical evidence, it is unclear whether patients with PDGFRA D842V may benefit from dasatinib or nilotinib and whether sorafenib may be effective against PDGFRA fusion_driven tumors with the D842V mutation (Ip et al., 2018; 30389923, Trent et al., 2011; ASCO Abstract 10006, von Mehren et al., 2016; ASCO Abstract 11010, Dewaele et al., 2008; 18794084, Paugh et al., 2013; 23970477, Lierman et al., 2009; 19212337, Sadovnik et al., 2014; 24407160, Weisberg et al., 2006; 17087936, von Bubnoff et al., 2011; 20972453). D842V mutation has been shown to be sensitive to avapritinib and regorafenib in several clinical studies of GIST (Kang et al., 2022; 34343033, Heinrich et al., 2020; 32615108, Evans et al., 2017; 29093181) but with reduced sensitivity to avapritinib when co_occurring with PDGFRA Y676C, G652E, QGPins, V658A, T674R, or G680R mutation (Grunewald et al., 2021; 32972961). The PDGFRA rearrangement in this tumor results in deletion of exons 8_9. The PDGFRA exon 8_9 deletion mutant was demonstrated to be active in the absence of ligand and has been characterized as transforming (Clarke et al., 2003; 12569364, Ozawa et al., 2010; 20889717). This mutant was sensitive to imatinib and the kinase inhibitor vatalanib (Ozawa et al., 2010; 20889717). PDGFRA mutation has been identified in 5.6% of Grade 3 and 5.4% of Grade 4 astrocytomas, 2.4% of Grade 3 oligodendrogliomas, and 12% (3/25) of gliosarcomas analyzed in COSMIC (Feb 2022)(Tate et al., 2019; 30371878). PDGFRA mutations have been reported in 0_5% of lower grade glioma and glioblastoma samples (cBio_Brennan et al., 2013; 24120142, Cancer Genome Atlas Research Network., 2008; 18772890, cBio_Hoadley et al., 2018; 29625048, cBio_Ellrott et al., 2018; 29596782, cBio_Taylor et al., 2018; 29622463, cBio_Gao et al., 2018; 29617662, cBio_Liu et al., 2018; 29625055, cBio_Sanchez_Vega et al., 2018; 29625050), Ceccarelli et al., 2016; 26824661, Cancer Genome Atlas Research Network., 2015; 26061751, cBio_Johnson et al., 2014; 24336570, cBio_Thomas et al., 2017; 28472509, cBio_Jones et al., 2013; 23817572). A retrospective analysis of TCGA glioma samples reported elevated expression of ERBB3 correlated with PDGFRA expression and co_expression of these genes was an indicator of poor prognosis in a GBM patient cohort (Song et al., 2018; 29888103). Amplification of PDGFRA has been associated with tumor grade and poor progression_free and overall survival in patients with glioblastoma (Alentorn et al., 2012; 23074200, Sottoriva et al., 2013; 23412337, Phillips et al., 2013; 23438035). In addition, PDGFRA amplification has been reported to occur in conjunction with IDH1 mutation in glioblastoma, and both alterations in the same tumor have been associated with poor patient prognosis (Phillips et al., 2013; 23438035). On the basis of extensive clinical evidence in solid tumors and hematologic cancers, PDGFRA activating alterations are associated with sensitivity to imatinib (Arefi et al., 2012; 22806436, Baccarani et al., 2007; 17666373, Cassier et al., 2012; 22718859, Chalmers et al., 2015; 25658984, Cools et al., 2003; 12660384, Curtis et al., 2007; 17555450, Debiec_Rychter et al., 2016; 15010069, Dileo et al., 2011; 20473908, Fanta et al., 2015; 24638008, Florian et al., 2006; 16406018, Frenard et al., 2016; 27051816, Griffin et al., 2003; 12808148, Heinrich et al., 2003; 14645423, Helbig et al., 2009; 19120352, Helbig et al., 2014; 24009127, Hus et al., 2011; 21093052, Ikezoe et al., 2010; 20303172, Intermesoli et al., 2009; 19735261, Jain et al., 2009; 19013640, Jovanovic et al., 2007; 17299092, Kang et al., 2012; 22150077, Klion et al., 2004; 14504092, Kobayashi et al., 2009; 19192229, Koc\u00e1kov\u00e1 et al., 2014; 24635438, Metzgeroth et al., 2008; 18950453, Murayama et al., 2012; 22645636, Ogbogu et al., 2009; 19910029, Ohnishi et al., 2006; 16856885, Pardanani et al., 2003; 12842979, Pardanani et al., 2004; 15284118, Qu et al., 2016; 27120808, Score et al., 2006; 16498388, Shah et al., 2011; 24669761, Sugimoto et al., 2015; 26319757, Volz et al., 2011; 20609486, von Bubnoff et al., 2005; 15618966, Walz et al., 2006; 16845659, Yoo et al., 2016; 26130666). Sorafenib has shown clinical and preclinical activity against the FIP1L1_PDGFRA fusion in chronic eosinophilic leukemia (CEL) and mutations associated with clinical resistance to imatinib and sunitinib in both CEL and gastrointestinal stromal tumor (GIST)(Fumagalli et al., 2012; ESMO Abstract 1491P, Al_Riyami et al., 2013; 23157309, Lierman et al., 2006; 16645167, Lierman et al., 2009; 19212337, Metzgeroth et al., 2012; 21818111, Roubaud et al., 2012; 22294526, Von Bubnoff et al., 2011; 20972453). Complete responses to nilotinib have been reported in patients with CEL or hypereosinophilic syndrome with FIP1L1_PDGFRA or activating mutations (Hochhaus et al., 2013; 24057647, Ikezoe et al., 2010; 20303172, Tabouret et al., 2011; 20832858); preclinical evidence has reported efficacy of nilotinib in the context of PDGFRA mutations associated with GIST (Dewaele et al., 2008; 18794084, Weisberg et al., 2006; 17087936). Patients with GIST harboring PDGFRA activating mutations have been reported to derive clinical benefit from treatment with sunitinib (Heinrich et al., 2006; ASCO Abstract 9502, Brohl et al., 2015; 26396737) or regorafenib (Grellety et al., 2015; 28031906, Kollar et al., 2014; 25905001). Preclinical studies have reported sensitivity of activating PDGFRA mutations and FIP1L1_PDGFRA fusion to dasatinib (Dewaele et al., 2008; 18794084, Lierman et al., 2009; 19212337). PDGFRA D842 mutations were reported to be sensitive to avapritinib in clinical (Heinrich et al., 2017; ASCO Abstract 11011, Evans et al., 2017; 29093181) and preclinical (Evans et al., 2017; 29093181) studies of GIST, and demonstrated sensitivity to ripretinib for 1 patient (Jaku et al., 2017; ASCO Abstract 2515). Strong clinical evidence in GIST associates PDGFRA D842V with resistance to imatinib and sunitinib (Piovesan et al., 2009; ASCO Abstract 10565, Trent et al., 2011; ASCO Abstract 10006, Raut et al., 2015; ASCO Abstract 10537, von Mehren et al., 2016; ASCO Abstract 11010, Farag et al., 2016; ASCO Abstract 11011, Cassier et al., 2012; 22718859, Debiec_Rychter et al., 2005; 15685537, Heinrich et al., 2003; 14645423, Heinrich et al., 2008; 18955451, Heinrich et al., 2008; 18955458, Heinrich et al., 2012; 22665524, Heinrich et al., 2012; 22745105, Yoo et al., 2015; 26130666, Prenen et al., 2006; 16638875); imatinib resistance has also been observed for cases with the D842V mutation in the context of PDGFRA fusions (Score et al., 2009; 18987650, Sorour et al., 2009; 19466970, Lierman et al., 2009; 19212337, Sadovnik et al., 2014; 24407160). Reduced sensitivity to regorafenib has been observed in 1 preliminary clinical study (von Mehren et al., 2016; ASCO Abstract 11010), to ponatinib in combination with FIP1L1_PDGFRA fusions in preclinical studies (Sadovnik et al., 2014; 24407160, Lierman et al., 2012; 22301675), and to avapritinib in combination with PDGFRA Y676C, G652E, QGPins, V658A, T674R, or G680R mutations based on limited clinical and preclinical data (Grunewald et al., 2021; 32972961). It is unclear whether patients with PDGFRA D842V may derive clinical benefit from dasatinib or nilotinib (Trent et al., 2011; ASCO Abstract 10006, von Mehren et al., 2016; ASCO Abstract 11010, Dewaele et al., 2008; 18794084, Paugh et al., 2013; 23970477, Lierman et al., 2009; 19212337, Sadovnik et al., 2014; 24407160, Weisberg et al., 2006; 17087936, von Bubnoff et al., 2011; 20972453). Although preclinical and preliminary clinical data in CEL suggest that the D842V mutation renders PDGFRA_rearranged tumors insensitive to sorafenib (Lierman et al., 2009; 19212337, Sadovnik et al., 2014; 24407160, von Bubnoff et al., 2011; 20972453), patients with D842V_positive GIST have benefited from sorafenib (Fumagalli et al., 2012; ESMO Abstract 1491P, Roubaud et al., 2012; 22294526, Dewaele et al., 2008; 18794084).", "Include": "true", "ClinicalTrialNote": "PDGFRA activating mutations may predict sensitivity to certain PDGFRA_targeted therapies. PDGFRA D842V predicts resistance to imatinib and sunitinib and may confer reduced sensitivity to regorafenib or ponatinib in the context of FIP1L1_PDGFRA fusion. Therefore, it is unclear whether dasatinib or nilotinib may provide clinical benefit for patients with PDGFRA D842V and whether sorafenib may be effective against PDGFRA_rearranged tumors with the D842V mutation. On the basis of limited clinical and preclinical evidence, D842V in combination with co_occurring mutations Y676C, G652E, QGPins, V658A, T674R, or G680R may have reduced sensitivity to avapritinib.", "Therapies": {"Therapy": [{"Name": null, "GenericName": "Sorafenib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Sorafenib is a kinase inhibitor that targets the RAF kinases, KIT, FLT3, RET, VEGFRs, and PDGFRs. It is FDA approved for the treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and recurrent or metastatic differentiated thyroid carcinoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical responses in patients with GIST, PDGFRA activating mutations may predict sensitivity to sorafenib (Fumagalli et al., 2012; ESMO Abstract 1491P)(Roubaud et al., 2012; 22294526). Although 4 patients with PDGFRA D842V_positive GIST have been reported to progress on sorafenib (von Mehren et al., 2016; ASCO Abstract 11010), 3 studies observed PRs for 4/10 and SD for 6/10 patients (Fumagalli et al., 2012; ESMO Abstract 1491P, Roubaud et al., 2012; 22294526; Schuetze et al., 2018; 29710216); this sensitivity is supported by preclinical data (Dewaele et al., 2008; 18794084). Based on preclinical and preliminary clinical evidence, PDGFRA D842V may confer reduced sensitivity to sorafenib (Trent et al., 2011; ASCO Abstract 10006, von Mehren et al., 2016; ASCO Abstract 11010, Dewaele et al., 2008; 18794084, Paugh et al., 2013; 23970477, Lierman et al., 2009; 19212337, Sadovnik et al., 2014; 24407160, Heinrich et al., 2012; 22665524, von Bubnoff et al., 2011; 20972453). Therefore, it is unclear whether this therapeutic strategy would be relevant here. </p> <p><b>Supporting Data:</b> Phase 2 studies of sorafenib plus temozolomide report limited activity in patients with relapsed glioblastoma multiforme (GBM) (Zustovich et al., 2013; 23898124; Reardon et al., 2011; 20443129). A Phase 1/2 trial of temsirolimus in combination with sorafenib in patients with glioblastoma was terminated at the Phase 2 interim analysis after patients failed to meet the primary endpoint of 6 month progression_free survival (Lee et al., 2012; 23099651). A Phase 2 trial of sorafenib and erlotinib in glioblastoma also did not meet its primary endpoint, and erlotinib clearance was increased by the addition of sorafenib (Peereboom et al., 2013; 23328813). In a Phase 1 trial in patients with high_grade glioma, the combination of sorafenib with radiation therapy (RT) and temozolomide (TMZ) resulted in increased toxicity and did not result in significant improvement in clinical efficacy compared with RT and TMZ alone (Hottinger et al., 2014; 24786603). In a clinical study of sorafenib in pediatric patients with low_grade astrocytoma, one patient achieved a partial response (PR), one had stable disease (SD), and 9 patients had progressive disease; this study was terminated early due to unexpectedly high disease progression rates (Karajannis et al., 2014; 24803676). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Imatinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Imatinib targets the BCR_ABL fusion protein, PDGFR, and KIT. It is FDA approved for the treatment of KIT_positive gastrointestinal stromal tumors (GIST), Ph+ chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), myelodysplastic syndrome/myeloproliferative syndrome (MDS/MPS), aggressive systemic mastocytosis without a D816V KIT mutation, hypereosinophilic syndrome and/or chronic eosinophilic leukemia, and dermatofibrosarcoma protuberans. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of strong clinical evidence, PDGFRA activating mutations (Cassier et al., 2012; 22718859, Dileo et al., 2011; 20473908, Fanta et al., 2015; 24638008, Heinrich et al., 2003; 14645423, Yoo et al., 2016; 26130666), fusions (Baccarani et al., 2007; 17666373, Curtis et al., 2007; 17555450, Griffin et al., 2003; 12808148, Helbig et al., 2009; 19120352, Klion et al., 2004; 14504092, Qu et al., 2016; 27120808, Metzgeroth et al., 2007; 17377585, Metzgeroth et al., 2008; 18950453, Ogbogu et al., 2009; 19910029, Sugimoto et al., 2015; 26319757), and expression (Frenard et al., 2016; 27051816) may predict sensitivity to imatinib. However, with the exception of rare cases of response (Farag et al., 2016; ASCO Abstract 11011)(Heinrich et al., 2008; 18955451), extensive clinical and preclinical data in GIST indicate that PDGFRA D842V confers resistance to imatinib, with progressive disease reported for 78% (61/78) of patients from various studies (Piovesan et al., 2009; ASCO Abstract 10565, Trent et al., 2011; ASCO Abstract 10006, Raut et al., 2015; ASCO Abstract 10537, von Mehren et al., 2016; ASCO Abstract 11010, Farag et al., 2016; ASCO Abstract 11011)(Cassier et al., 2012; 22718859, Debiec_Rychter et al., 2005; 15685537, Heinrich et al., 2003; 14645423, Heinrich et al., 2008; 18955451, Heinrich et al., 2008; 18955458, Heinrich et al., 2012; 22665524, Heinrich et al., 2012; 22745105, Yoo et al., 2015; 26130666); several studies observed shorter median progression_free survival with imatinib for patients with PDGRA D842V than for patients with other PDGFRA mutations (2.8_8.0 vs. 24_30 months) (Farag et al., 2016; ASCO Abstract 11011)(Cassier et al., 2012; 22718859, Yoo et al., 2015; 26130666). </p> <p><b>Supporting Data:</b> In a clinical study where patients with recurrent glioblastoma were given imatinib, 2/24 patients achieved a PR, 10 patients reported SD, and median OS and PFS was observed to be 6.2 and 3 months, respectively (Hassler et al., 2014; 25674429). However, other Phase 2 clinical trials of imatinib have reported no anti_tumor activity, with a study of 231 patients with glioblastoma reporting a radiographic response rate of only 3.4% (Razis et al., 2009; 19789313, Reardon et al., 2009; 19904263). In another Phase 2 study, imatinib plus hydroxyurea was shown to be well tolerated among patients with recurrent/progressive low_grade glioma, but had negligible antitumor activity (Reardon et al., 2012; 22371319). </p>", "ApprovedUses": null, "Effect": "Resistant", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}]}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT03970447", "Include": "true"}, {"nctId": "NCT05159245", "Include": "true"}, {"nctId": "NCT04771520", "Include": "true"}]}}, {"Name": "deletion exons 8_9", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "deletion exons 8_9"}}, "Interpretation": "PDGFRA encodes platelet_derived growth factor receptor alpha (PDGFR_alpha), a tyrosine kinase receptor that, upon binding of cognate ligands (PDGFA or PDGFB), activates several signaling pathways, including PI3K and MAPK (Andrae et al., 2008; 18483217). PDGFR aberrations, including point mutations, translocations, amplification, and/or overexpression, have been associated with various malignancies (Fletcher, 2004; 15175998). The PDGFRA exon 18 mutation D842V has been characterized as activating and is associated with clinical resistance to imatinib and sunitinib in GISTs (von Mehren et al., 2016; ASCO Abstract 11010, Farag et al., 2016; ASCO Abstract 11011, Cassier et al., 2012; 22718859, Debiec_Rychter et al., 2005; 15685537, Heinrich et al., 2003; 14645423, Heinrich et al., 2008; 18955451, Heinrich et al., 2008; 18955458, Heinrich et al., 2012; 22665524, Heinrich et al., 2012; 22745105, Yoo et al., 2015; 26130666). On the basis of preclinical and preliminary clinical evidence, it is unclear whether patients with PDGFRA D842V may benefit from dasatinib or nilotinib and whether sorafenib may be effective against PDGFRA fusion_driven tumors with the D842V mutation (Ip et al., 2018; 30389923, Trent et al., 2011; ASCO Abstract 10006, von Mehren et al., 2016; ASCO Abstract 11010, Dewaele et al., 2008; 18794084, Paugh et al., 2013; 23970477, Lierman et al., 2009; 19212337, Sadovnik et al., 2014; 24407160, Weisberg et al., 2006; 17087936, von Bubnoff et al., 2011; 20972453). D842V mutation has been shown to be sensitive to avapritinib and regorafenib in several clinical studies of GIST (Kang et al., 2022; 34343033, Heinrich et al., 2020; 32615108, Evans et al., 2017; 29093181) but with reduced sensitivity to avapritinib when co_occurring with PDGFRA Y676C, G652E, QGPins, V658A, T674R, or G680R mutation (Grunewald et al., 2021; 32972961). The PDGFRA rearrangement in this tumor results in deletion of exons 8_9. The PDGFRA exon 8_9 deletion mutant was demonstrated to be active in the absence of ligand and has been characterized as transforming (Clarke et al., 2003; 12569364, Ozawa et al., 2010; 20889717). This mutant was sensitive to imatinib and the kinase inhibitor vatalanib (Ozawa et al., 2010; 20889717). PDGFRA mutation has been identified in 5.6% of Grade 3 and 5.4% of Grade 4 astrocytomas, 2.4% of Grade 3 oligodendrogliomas, and 12% (3/25) of gliosarcomas analyzed in COSMIC (Feb 2022)(Tate et al., 2019; 30371878). PDGFRA mutations have been reported in 0_5% of lower grade glioma and glioblastoma samples (cBio_Brennan et al., 2013; 24120142, Cancer Genome Atlas Research Network., 2008; 18772890, cBio_Hoadley et al., 2018; 29625048, cBio_Ellrott et al., 2018; 29596782, cBio_Taylor et al., 2018; 29622463, cBio_Gao et al., 2018; 29617662, cBio_Liu et al., 2018; 29625055, cBio_Sanchez_Vega et al., 2018; 29625050), Ceccarelli et al., 2016; 26824661, Cancer Genome Atlas Research Network., 2015; 26061751, cBio_Johnson et al., 2014; 24336570, cBio_Thomas et al., 2017; 28472509, cBio_Jones et al., 2013; 23817572). A retrospective analysis of TCGA glioma samples reported elevated expression of ERBB3 correlated with PDGFRA expression and co_expression of these genes was an indicator of poor prognosis in a GBM patient cohort (Song et al., 2018; 29888103). Amplification of PDGFRA has been associated with tumor grade and poor progression_free and overall survival in patients with glioblastoma (Alentorn et al., 2012; 23074200, Sottoriva et al., 2013; 23412337, Phillips et al., 2013; 23438035). In addition, PDGFRA amplification has been reported to occur in conjunction with IDH1 mutation in glioblastoma, and both alterations in the same tumor have been associated with poor patient prognosis (Phillips et al., 2013; 23438035). On the basis of extensive clinical evidence in solid tumors and hematologic cancers, PDGFRA activating alterations are associated with sensitivity to imatinib (Arefi et al., 2012; 22806436, Baccarani et al., 2007; 17666373, Cassier et al., 2012; 22718859, Chalmers et al., 2015; 25658984, Cools et al., 2003; 12660384, Curtis et al., 2007; 17555450, Debiec_Rychter et al., 2016; 15010069, Dileo et al., 2011; 20473908, Fanta et al., 2015; 24638008, Florian et al., 2006; 16406018, Frenard et al., 2016; 27051816, Griffin et al., 2003; 12808148, Heinrich et al., 2003; 14645423, Helbig et al., 2009; 19120352, Helbig et al., 2014; 24009127, Hus et al., 2011; 21093052, Ikezoe et al., 2010; 20303172, Intermesoli et al., 2009; 19735261, Jain et al., 2009; 19013640, Jovanovic et al., 2007; 17299092, Kang et al., 2012; 22150077, Klion et al., 2004; 14504092, Kobayashi et al., 2009; 19192229, Koc\u00e1kov\u00e1 et al., 2014; 24635438, Metzgeroth et al., 2008; 18950453, Murayama et al., 2012; 22645636, Ogbogu et al., 2009; 19910029, Ohnishi et al., 2006; 16856885, Pardanani et al., 2003; 12842979, Pardanani et al., 2004; 15284118, Qu et al., 2016; 27120808, Score et al., 2006; 16498388, Shah et al., 2011; 24669761, Sugimoto et al., 2015; 26319757, Volz et al., 2011; 20609486, von Bubnoff et al., 2005; 15618966, Walz et al., 2006; 16845659, Yoo et al., 2016; 26130666). Sorafenib has shown clinical and preclinical activity against the FIP1L1_PDGFRA fusion in chronic eosinophilic leukemia (CEL) and mutations associated with clinical resistance to imatinib and sunitinib in both CEL and gastrointestinal stromal tumor (GIST)(Fumagalli et al., 2012; ESMO Abstract 1491P, Al_Riyami et al., 2013; 23157309, Lierman et al., 2006; 16645167, Lierman et al., 2009; 19212337, Metzgeroth et al., 2012; 21818111, Roubaud et al., 2012; 22294526, Von Bubnoff et al., 2011; 20972453). Complete responses to nilotinib have been reported in patients with CEL or hypereosinophilic syndrome with FIP1L1_PDGFRA or activating mutations (Hochhaus et al., 2013; 24057647, Ikezoe et al., 2010; 20303172, Tabouret et al., 2011; 20832858); preclinical evidence has reported efficacy of nilotinib in the context of PDGFRA mutations associated with GIST (Dewaele et al., 2008; 18794084, Weisberg et al., 2006; 17087936). Patients with GIST harboring PDGFRA activating mutations have been reported to derive clinical benefit from treatment with sunitinib (Heinrich et al., 2006; ASCO Abstract 9502, Brohl et al., 2015; 26396737) or regorafenib (Grellety et al., 2015; 28031906, Kollar et al., 2014; 25905001). Preclinical studies have reported sensitivity of activating PDGFRA mutations and FIP1L1_PDGFRA fusion to dasatinib (Dewaele et al., 2008; 18794084, Lierman et al., 2009; 19212337). PDGFRA D842 mutations were reported to be sensitive to avapritinib in clinical (Heinrich et al., 2017; ASCO Abstract 11011, Evans et al., 2017; 29093181) and preclinical (Evans et al., 2017; 29093181) studies of GIST, and demonstrated sensitivity to ripretinib for 1 patient (Jaku et al., 2017; ASCO Abstract 2515). Strong clinical evidence in GIST associates PDGFRA D842V with resistance to imatinib and sunitinib (Piovesan et al., 2009; ASCO Abstract 10565, Trent et al., 2011; ASCO Abstract 10006, Raut et al., 2015; ASCO Abstract 10537, von Mehren et al., 2016; ASCO Abstract 11010, Farag et al., 2016; ASCO Abstract 11011, Cassier et al., 2012; 22718859, Debiec_Rychter et al., 2005; 15685537, Heinrich et al., 2003; 14645423, Heinrich et al., 2008; 18955451, Heinrich et al., 2008; 18955458, Heinrich et al., 2012; 22665524, Heinrich et al., 2012; 22745105, Yoo et al., 2015; 26130666, Prenen et al., 2006; 16638875); imatinib resistance has also been observed for cases with the D842V mutation in the context of PDGFRA fusions (Score et al., 2009; 18987650, Sorour et al., 2009; 19466970, Lierman et al., 2009; 19212337, Sadovnik et al., 2014; 24407160). Reduced sensitivity to regorafenib has been observed in 1 preliminary clinical study (von Mehren et al., 2016; ASCO Abstract 11010), to ponatinib in combination with FIP1L1_PDGFRA fusions in preclinical studies (Sadovnik et al., 2014; 24407160, Lierman et al., 2012; 22301675), and to avapritinib in combination with PDGFRA Y676C, G652E, QGPins, V658A, T674R, or G680R mutations based on limited clinical and preclinical data (Grunewald et al., 2021; 32972961). It is unclear whether patients with PDGFRA D842V may derive clinical benefit from dasatinib or nilotinib (Trent et al., 2011; ASCO Abstract 10006, von Mehren et al., 2016; ASCO Abstract 11010, Dewaele et al., 2008; 18794084, Paugh et al., 2013; 23970477, Lierman et al., 2009; 19212337, Sadovnik et al., 2014; 24407160, Weisberg et al., 2006; 17087936, von Bubnoff et al., 2011; 20972453). Although preclinical and preliminary clinical data in CEL suggest that the D842V mutation renders PDGFRA_rearranged tumors insensitive to sorafenib (Lierman et al., 2009; 19212337, Sadovnik et al., 2014; 24407160, von Bubnoff et al., 2011; 20972453), patients with D842V_positive GIST have benefited from sorafenib (Fumagalli et al., 2012; ESMO Abstract 1491P, Roubaud et al., 2012; 22294526, Dewaele et al., 2008; 18794084).", "Include": "true", "ClinicalTrialNote": "PDGFRA activating mutations may predict sensitivity to certain PDGFRA_targeted therapies. PDGFRA D842V predicts resistance to imatinib and sunitinib and may confer reduced sensitivity to regorafenib or ponatinib in the context of FIP1L1_PDGFRA fusion. Therefore, it is unclear whether dasatinib or nilotinib may provide clinical benefit for patients with PDGFRA D842V and whether sorafenib may be effective against PDGFRA_rearranged tumors with the D842V mutation. On the basis of limited clinical and preclinical evidence, D842V in combination with co_occurring mutations Y676C, G652E, QGPins, V658A, T674R, or G680R may have reduced sensitivity to avapritinib.", "Therapies": {"Therapy": [{"Name": null, "GenericName": "Sorafenib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Sorafenib is a kinase inhibitor that targets the RAF kinases, KIT, FLT3, RET, VEGFRs, and PDGFRs. It is FDA approved for the treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and recurrent or metastatic differentiated thyroid carcinoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical responses in patients with GIST, PDGFRA activating mutations may predict sensitivity to sorafenib (Fumagalli et al., 2012; ESMO Abstract 1491P)(Roubaud et al., 2012; 22294526). Although 4 patients with PDGFRA D842V_positive GIST have been reported to progress on sorafenib (von Mehren et al., 2016; ASCO Abstract 11010), 3 studies observed PRs for 4/10 and SD for 6/10 patients (Fumagalli et al., 2012; ESMO Abstract 1491P, Roubaud et al., 2012; 22294526; Schuetze et al., 2018; 29710216); this sensitivity is supported by preclinical data (Dewaele et al., 2008; 18794084). Based on preclinical and preliminary clinical evidence, PDGFRA D842V may confer reduced sensitivity to sorafenib (Trent et al., 2011; ASCO Abstract 10006, von Mehren et al., 2016; ASCO Abstract 11010, Dewaele et al., 2008; 18794084, Paugh et al., 2013; 23970477, Lierman et al., 2009; 19212337, Sadovnik et al., 2014; 24407160, Heinrich et al., 2012; 22665524, von Bubnoff et al., 2011; 20972453). Therefore, it is unclear whether this therapeutic strategy would be relevant here. </p> <p><b>Supporting Data:</b> Phase 2 studies of sorafenib plus temozolomide report limited activity in patients with relapsed glioblastoma multiforme (GBM) (Zustovich et al., 2013; 23898124; Reardon et al., 2011; 20443129). A Phase 1/2 trial of temsirolimus in combination with sorafenib in patients with glioblastoma was terminated at the Phase 2 interim analysis after patients failed to meet the primary endpoint of 6 month progression_free survival (Lee et al., 2012; 23099651). A Phase 2 trial of sorafenib and erlotinib in glioblastoma also did not meet its primary endpoint, and erlotinib clearance was increased by the addition of sorafenib (Peereboom et al., 2013; 23328813). In a Phase 1 trial in patients with high_grade glioma, the combination of sorafenib with radiation therapy (RT) and temozolomide (TMZ) resulted in increased toxicity and did not result in significant improvement in clinical efficacy compared with RT and TMZ alone (Hottinger et al., 2014; 24786603). In a clinical study of sorafenib in pediatric patients with low_grade astrocytoma, one patient achieved a partial response (PR), one had stable disease (SD), and 9 patients had progressive disease; this study was terminated early due to unexpectedly high disease progression rates (Karajannis et al., 2014; 24803676). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Imatinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Imatinib targets the BCR_ABL fusion protein, PDGFR, and KIT. It is FDA approved for the treatment of KIT_positive gastrointestinal stromal tumors (GIST), Ph+ chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), myelodysplastic syndrome/myeloproliferative syndrome (MDS/MPS), aggressive systemic mastocytosis without a D816V KIT mutation, hypereosinophilic syndrome and/or chronic eosinophilic leukemia, and dermatofibrosarcoma protuberans. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of strong clinical evidence, PDGFRA activating mutations (Cassier et al., 2012; 22718859, Dileo et al., 2011; 20473908, Fanta et al., 2015; 24638008, Heinrich et al., 2003; 14645423, Yoo et al., 2016; 26130666), fusions (Baccarani et al., 2007; 17666373, Curtis et al., 2007; 17555450, Griffin et al., 2003; 12808148, Helbig et al., 2009; 19120352, Klion et al., 2004; 14504092, Qu et al., 2016; 27120808, Metzgeroth et al., 2007; 17377585, Metzgeroth et al., 2008; 18950453, Ogbogu et al., 2009; 19910029, Sugimoto et al., 2015; 26319757), and expression (Frenard et al., 2016; 27051816) may predict sensitivity to imatinib. However, with the exception of rare cases of response (Farag et al., 2016; ASCO Abstract 11011)(Heinrich et al., 2008; 18955451), extensive clinical and preclinical data in GIST indicate that PDGFRA D842V confers resistance to imatinib, with progressive disease reported for 78% (61/78) of patients from various studies (Piovesan et al., 2009; ASCO Abstract 10565, Trent et al., 2011; ASCO Abstract 10006, Raut et al., 2015; ASCO Abstract 10537, von Mehren et al., 2016; ASCO Abstract 11010, Farag et al., 2016; ASCO Abstract 11011)(Cassier et al., 2012; 22718859, Debiec_Rychter et al., 2005; 15685537, Heinrich et al., 2003; 14645423, Heinrich et al., 2008; 18955451, Heinrich et al., 2008; 18955458, Heinrich et al., 2012; 22665524, Heinrich et al., 2012; 22745105, Yoo et al., 2015; 26130666); several studies observed shorter median progression_free survival with imatinib for patients with PDGRA D842V than for patients with other PDGFRA mutations (2.8_8.0 vs. 24_30 months) (Farag et al., 2016; ASCO Abstract 11011)(Cassier et al., 2012; 22718859, Yoo et al., 2015; 26130666). </p> <p><b>Supporting Data:</b> In a clinical study where patients with recurrent glioblastoma were given imatinib, 2/24 patients achieved a PR, 10 patients reported SD, and median OS and PFS was observed to be 6.2 and 3 months, respectively (Hassler et al., 2014; 25674429). However, other Phase 2 clinical trials of imatinib have reported no anti_tumor activity, with a study of 231 patients with glioblastoma reporting a radiographic response rate of only 3.4% (Razis et al., 2009; 19789313, Reardon et al., 2009; 19904263). In another Phase 2 study, imatinib plus hydroxyurea was shown to be well tolerated among patients with recurrent/progressive low_grade glioma, but had negligible antitumor activity (Reardon et al., 2012; 22371319). </p>", "ApprovedUses": null, "Effect": "Resistant", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}]}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT03970447", "Include": "true"}, {"nctId": "NCT05159245", "Include": "true"}, {"nctId": "NCT04771520", "Include": "true"}]}}]}, "ReferenceLinks": null}, {"Name": "PTEN", "Include": "true", "Alterations": {"Alteration": {"Name": "K342N", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "K342N"}}, "Interpretation": "PTEN encodes an inositol phosphatase that functions as a tumor suppressor by negatively regulating the PI3K_AKT_mTOR pathway; loss of PTEN can lead to uncontrolled cell growth and suppression of apoptosis (Simpson and Parsons, 2001; 11237521). Alterations such as seen here may disrupt PTEN function or expression (Campbell et al., 2003; 12857747, Rodr\u00edguez_Escudero et al., 2011; 21828076, He et al., 2013; 23475934, Han et al., 2000; 10866302, Myers et al., 1998; 9811831, Pradella et al., 2014; 24498881, Kim et al., 2011; 21536651, Denning et al., 2007; 17213812, Hlobilkova et al., 2006; 16619501, Redfern et al., 2010; 20718038, Shenoy et al., 2012; 22505997, Wang et al., 2009; 19329485, Okumura et al., 2006; 16829519, Lee et al., 1999; 10555148, Maxwell et al., 1998; 9635567, Risinger et al., 1998; 9865913, Kato et al., 2000; 11051241, Fenton et al, 2012; 22891331, Ngeow et al., 2012; 23066114, Lobo et al., 2009; 19457929, Liu et al., 2014; 23995781, Maehama et al., 2001; 11395408, De Vivo et al., 2000; 10807691, Ramaswamy et al., 1999; 10051603, Liu et al., 2005; 15988030, Karoui et al., 2004; 15026806, Gil et al., 2015; 25875300, Furnari et al., 1998; 9823298, Spinelli et al., 2015; 25527629, Mingo et al., 2018; 29706633, Wang et al., 2010; 20538496, Andr\u00e9s_Pons et al., 2007; 17942903, Butler et al., 2005; 15805158, Lee et al., 1999; 10555148, Georgescu et al., 1999; 10468583, Staal et al., 2002; 12085208, Nguyen et al., 2013; 24292679, Rahdar et al., 2009; 19114656, Das et al., 2003; 12808147, Wang et al., 2008; 18498243, Valiente et al., 2005; 15951562, Nguyen et al., 2015; 25263454, Shan et al., 2020; 32704382). Studies in the literature have indicated that PTEN alterations (mutation or homozygous deletion) occur most frequently in glioblastoma (GBM), less frequently in anaplastic astrocytoma, and rarely in lower grade glioma subtypes including low grade astrocytoma, oligodendroglioma, oligoastrocytoma, and ependymoma (Zhou et al., 1999; 10096247, Rasheed et al., 1997; 9331072, Davies et al., 1999; 10188904, Smith et al., 2001; 11504770, Lin et al., 1998; 9796977, Schmidt et al., 1999; 10560660, Kato et al., 2000; 11051241, Furnari et al., 2007; 17974913). One study detected PTEN mutation in 42% (97/232) and loss in 10% (24/232) of IDH_wildtype GBM samples analyzed (Yan et al. 2020; DOI:10.1200/PO.19.00385). In the TCGA dataset, PTEN mutation was observed in 23% of GBM cases and PTEN deletion was reported in 7% of cases (cBio_Brennan et al., 2013; 24120142), while in the Lower Grade Glioma TCGA dataset, PTEN mutation was observed in 4% of cases and homozygous deletion observed in 1.2% of cases (Cancer Genome Atlas Research Network., 2015; 26061751). Decreased PTEN expression is associated with the higher grade GBM tumors (Sano et al., 1999; 10213484). Loss of PTEN correlated with significantly worse prognosis in all grades of gliomas (Lin et al., 1998; 9796977, Srividya et al., 2011; 21134002). PTEN loss or mutation leads to activation of the PI3K_AKT_mTOR pathway and may predict sensitivity to inhibitors of this pathway (Courtney et al., 2010; 20085938, Simpson and Parsons, 2001; 11237521, Patnaik et al., 2016; 27672108, Milella et al., 2017; 28220839). Clinical studies in glioblastoma have not observed an association between PTEN deficiency and response to everolimus or temsirolimus (Galanis et al., 2005; 15998902, Kreisl et al., 2009; 19018475, Mason et al., 2011; 22160854). Preclinical data indicate that PTEN loss or inactivation may predict sensitivity to PARP inhibitors (Mendes_Pereira et al., 2009; 20049735, Shen et al., 2013; 23881923, Chatterjee et al., 2013; 23565244, McCormick et al., 2016; 26905328, Forster et al., 2011; 21468130), and clinical benefit has been observed for patients with PTEN_altered breast cancer including triple negative breast cancer (Gruber et al., 2019; ASCO Abstract 3006, Eikesdal et al., 2021; 33242536), ovarian cancer (Dougherty et al., 2014; ASCO Abstract 5536), uterine leiomyosarcoma (Pan et al., 2021; 33970096), and endometrial cancer (Forster et al., 2011; 21468130) treated with PARP inhibitors. However, some studies have reported a lack of association between PTEN mutation and PARP inhibitor sensitivity (Sandhu et al., 2013; 23810788, Romero et al., 2020; 32988624, Piha_Paul et al., 2018; AACR Abstract A096). PTEN mutations underlie several inherited disorders, collectively termed PTEN hamartoma tumor syndrome (PHTS), which include Cowden syndrome (CS) and its variant Lhermitte_Duclos disease (LD), Bannayan_Riley_Ruvalcaba syndrome (BRRS), PTEN_related Proteus syndrome (PS), and Proteus_like syndrome (Blumenthal and Dennis, 2008; 18781191, Orloff and Eng, 2008; 18794875). The mutation rate for PTEN in these disorders ranges from 20 to 85% of patients (Blumenthal and Dennis, 2008; 18781191, Zbuk and Eng, 2007; 17167516). The estimated incidence of Cowden syndrome is 1/200,000, which may be an underestimate due to the high variability of this disorder (Blumenthal and Dennis, 2008; 18781191). Given the association between PTEN and these inherited syndromes, in the appropriate clinical context, germline testing for mutations affecting PTEN is recommended.", "Include": "true", "ClinicalTrialNote": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04644068", "Include": "true"}, {"nctId": "NCT04341259", "Include": "true"}, {"nctId": "NCT02264678", "Include": "true"}, {"nctId": "NCT04740190", "Include": "true"}, {"nctId": "NCT04001569", "Include": "true"}, {"nctId": "NCT05035745", "Include": "true"}, {"nctId": "NCT03772561", "Include": "true"}, {"nctId": "NCT04614909", "Include": "true"}, {"nctId": "NCT05076513", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "CDKN2A/B", "Include": "true", "Alterations": {"Alteration": [{"Name": "CDKN2B loss", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "CDKN2B loss"}}, "Interpretation": "CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b (Quelle et al., 1995; 8521522, Sharpless, 2005; 15878778). Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth_suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6_cyclin_Rb pathway and loss of cell cycle control (Gazzeri et al., 1998; 9484839, Roussel, 1999; 10498883). The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition (Sherr et al., 2005; 16869746, Ozenne et al., 2010; 20549699). One or more alterations observed here are predicted to result in p16INK4a loss of function (Ruas et al., 1999; 10498896, Jones et al., 2007; 17909018, Haferkamp et al., 2008; 18843795, Huot et al., 2002; 12417717, Rizos et al., 2001; 11518711, Gombart et al., 1997; 9324288, Yang et al., 1995; 7780957, Parry and Peters, 1996; 8668202, Greenblatt et al., 2003; 12606942, Yarbrough et al., 1999; 10491434, Poi et al., 2001; 11255261, Byeon et al., 1998; 9660926, Kannengiesser et al., 2009; 19260062, Lal et al., 2000; 10719365, Koh et al., 1995; 7777061, McKenzie et al., 2010; 20340136, Miller et al., 2011; 21462282, Arap et al., 1997; 905385, Scaini et al., 2014; 24659262, Jenkins et al., 2013; 23190892, Walker et al., 1999; 10389768, Rutter et al., 2003; 12853981). One or more alterations seen here are predicted to result in p14ARF loss of function (Rizos et al., 2001; 11518711, Itahana and Zhang, 2008; 18538737, Zhang and Xiong, 1999; 10360174, Zhang et al., 1998; 9529249, Rutter et al., 2003; 12853981). CDKN2B alterations such as seen here are predicted to inactivate p15INK4b (Jafri et al., 2015; 25873077). Concurrent putative homozygous deletion of CDKN2A and CDKN2B has been reported in 35% of patients with gliomas (cBio_Ceccarelli et al., 2016; 26824661) and detected more frequently in patients with glioblastoma multiforme (GBM; 58%)(cBio_Brennan et al., 2013; 24120142) than in those with lower grade gliomas (6%) (Jonsson et al., 2019; 31263031). In other studies, loss of CDKN2A/B by deletion has been reported in up to 78% of astrocytomas (including anaplastic astrocytomas and GBM) (Verhaak et al., 2010; 20129251, Sottoriva et al., 2013; 23412337, Weber et al., 2007; 16909113). A study found homozygous deletion of both p16INK4a and p14ARF in 26% (13/50) of glioblastomas (GBMs); 18% (9/50) of cases showed homozygous deletion of the p14ARF_encoding locus alone (Nakamura et al., 2001; 11303791). One study detected CDKN2A/B loss in 69% (161/232) and mutation in 2.6% (6/232) of IDH_wildtype GBM samples analyzed (Yan et al. 2020; DOI:10.1200/PO.19.00385). Decreased p14ARF and p16INK4a expression levels were found to be tightly associated in a study of glioma samples (Chakravarti et al., 2001; 11489817). Homozygous deletion of the genomic region including CDKN2A and CDKN2B has been found to be associated with poor prognosis in GBM and likely serves as an early event in GBM progression (Feng et al., 2012; 21713760, Sottoriva et al., 2013; 23412337). In addition, expression of p16INK4a has been found to be lower in patients with high grade malignant gliomas compared to patients with low grade gliomas, and loss of p16INK4a expression has been associated with shorter overall survival in pilocytic astrocytomas (Raabe et al., 2011; 21636552, Liu et al., 2011; 21843312). Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib (Konecny et al., 2011; 21278246, Katsumi et al., 2011; 21871868, Cen et al., 2012; 22711607, Logan et al., 2013; 23898052). Clinical data in mesothelioma, breast cancer, and uterine leiomyosarcoma indicate that CDKN2A loss may predict sensitivity to abemaciclib (Fennell et al., 2022; 35157829) and palbociclib treatment (Elvin et al., 2017; 28283584, Gao et al., 2015; 26715889). However, multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents (Gopalan et al., 2014; ASCO Abstract 8077, Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557)(DeMichele et al., 2014; 25501126, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Johnson et al., 2014; 24797823); it is not known whether CDK4/6 inhibitors would be beneficial in this case. Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors (Van Maerken et al., 2011; 21460101, Gamble et al., 2012; 21725357), the clinical relevance of p14ARF as a predictive biomarker is not clear. Because the p15INK4b protein encoded by CDKN2B is known to inhibit CDK4, tumors with CDKN2B mutation or loss may predict sensitivity to CDK4/6 inhibitors, such as ribociclib, abemaciclib, and palbociclib (Infante et al., 2014; ASCO Abstract 2528, Shapiro et al., 2013; ASCO Abstract 2500)(Flaherty et al., 2012; 22090362, Dickson et al., 2013; 23569312, Finn et al., 2015; 25524798, DeMichele et al., 2014; 25501126). Germline CDKN2A mutation is associated with melanoma_pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer (Whelan et al., 1995; 7666917). Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma (Hansson, 2010; 20687502, Hogg et al., 1998; 9479083). CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases (De Unamuno et al., 2018; 29543703, Soura et al., 2016; 26892650, Huerta et al., 2018; 29405243). CDKN2A alteration has also been implicated in familial melanoma_astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors (Kaufman et al., 1993; 8414022, Bahuau et al., 1998; 9622062, Chan et al., 2017; 28699883). In the appropriate clinical context, germline testing of CDKN2A is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}, {"Name": "CDKN2A loss", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "CDKN2A loss"}}, "Interpretation": "CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b (Quelle et al., 1995; 8521522, Sharpless, 2005; 15878778). Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth_suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6_cyclin_Rb pathway and loss of cell cycle control (Gazzeri et al., 1998; 9484839, Roussel, 1999; 10498883). The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition (Sherr et al., 2005; 16869746, Ozenne et al., 2010; 20549699). One or more alterations observed here are predicted to result in p16INK4a loss of function (Ruas et al., 1999; 10498896, Jones et al., 2007; 17909018, Haferkamp et al., 2008; 18843795, Huot et al., 2002; 12417717, Rizos et al., 2001; 11518711, Gombart et al., 1997; 9324288, Yang et al., 1995; 7780957, Parry and Peters, 1996; 8668202, Greenblatt et al., 2003; 12606942, Yarbrough et al., 1999; 10491434, Poi et al., 2001; 11255261, Byeon et al., 1998; 9660926, Kannengiesser et al., 2009; 19260062, Lal et al., 2000; 10719365, Koh et al., 1995; 7777061, McKenzie et al., 2010; 20340136, Miller et al., 2011; 21462282, Arap et al., 1997; 905385, Scaini et al., 2014; 24659262, Jenkins et al., 2013; 23190892, Walker et al., 1999; 10389768, Rutter et al., 2003; 12853981). One or more alterations seen here are predicted to result in p14ARF loss of function (Rizos et al., 2001; 11518711, Itahana and Zhang, 2008; 18538737, Zhang and Xiong, 1999; 10360174, Zhang et al., 1998; 9529249, Rutter et al., 2003; 12853981). CDKN2B alterations such as seen here are predicted to inactivate p15INK4b (Jafri et al., 2015; 25873077). Concurrent putative homozygous deletion of CDKN2A and CDKN2B has been reported in 35% of patients with gliomas (cBio_Ceccarelli et al., 2016; 26824661) and detected more frequently in patients with glioblastoma multiforme (GBM; 58%)(cBio_Brennan et al., 2013; 24120142) than in those with lower grade gliomas (6%) (Jonsson et al., 2019; 31263031). In other studies, loss of CDKN2A/B by deletion has been reported in up to 78% of astrocytomas (including anaplastic astrocytomas and GBM) (Verhaak et al., 2010; 20129251, Sottoriva et al., 2013; 23412337, Weber et al., 2007; 16909113). A study found homozygous deletion of both p16INK4a and p14ARF in 26% (13/50) of glioblastomas (GBMs); 18% (9/50) of cases showed homozygous deletion of the p14ARF_encoding locus alone (Nakamura et al., 2001; 11303791). One study detected CDKN2A/B loss in 69% (161/232) and mutation in 2.6% (6/232) of IDH_wildtype GBM samples analyzed (Yan et al. 2020; DOI:10.1200/PO.19.00385). Decreased p14ARF and p16INK4a expression levels were found to be tightly associated in a study of glioma samples (Chakravarti et al., 2001; 11489817). Homozygous deletion of the genomic region including CDKN2A and CDKN2B has been found to be associated with poor prognosis in GBM and likely serves as an early event in GBM progression (Feng et al., 2012; 21713760, Sottoriva et al., 2013; 23412337). In addition, expression of p16INK4a has been found to be lower in patients with high grade malignant gliomas compared to patients with low grade gliomas, and loss of p16INK4a expression has been associated with shorter overall survival in pilocytic astrocytomas (Raabe et al., 2011; 21636552, Liu et al., 2011; 21843312). Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib (Konecny et al., 2011; 21278246, Katsumi et al., 2011; 21871868, Cen et al., 2012; 22711607, Logan et al., 2013; 23898052). Clinical data in mesothelioma, breast cancer, and uterine leiomyosarcoma indicate that CDKN2A loss may predict sensitivity to abemaciclib (Fennell et al., 2022; 35157829) and palbociclib treatment (Elvin et al., 2017; 28283584, Gao et al., 2015; 26715889). However, multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents (Gopalan et al., 2014; ASCO Abstract 8077, Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557)(DeMichele et al., 2014; 25501126, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Johnson et al., 2014; 24797823); it is not known whether CDK4/6 inhibitors would be beneficial in this case. Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors (Van Maerken et al., 2011; 21460101, Gamble et al., 2012; 21725357), the clinical relevance of p14ARF as a predictive biomarker is not clear. Because the p15INK4b protein encoded by CDKN2B is known to inhibit CDK4, tumors with CDKN2B mutation or loss may predict sensitivity to CDK4/6 inhibitors, such as ribociclib, abemaciclib, and palbociclib (Infante et al., 2014; ASCO Abstract 2528, Shapiro et al., 2013; ASCO Abstract 2500)(Flaherty et al., 2012; 22090362, Dickson et al., 2013; 23569312, Finn et al., 2015; 25524798, DeMichele et al., 2014; 25501126). Germline CDKN2A mutation is associated with melanoma_pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer (Whelan et al., 1995; 7666917). Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma (Hansson, 2010; 20687502, Hogg et al., 1998; 9479083). CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases (De Unamuno et al., 2018; 29543703, Soura et al., 2016; 26892650, Huerta et al., 2018; 29405243). CDKN2A alteration has also been implicated in familial melanoma_astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors (Kaufman et al., 1993; 8414022, Bahuau et al., 1998; 9622062, Chan et al., 2017; 28699883). In the appropriate clinical context, germline testing of CDKN2A is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}]}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). Low_level MSI has been reported in 5_9% of glioblastoma (GBM) samples (Martinez et al., 2004; 15331927, Martinez et al., 2005; 15672285, Martinez et al., 2007; 17498554). A large_scale study did not find high_level microsatellite instability (MSI_H) in any of 129 GBM samples (Martinez et al., 2004; 15331927), although a small_scale study reported MSI_H in 4 of 15 pediatric GBMs and 1 of 12 adult GBMs (Szybka et al., 2003; 12908754). The frequency of MSI has been reported to be increased in relapsed compared to primary GBM (Martinez et al., 2004; 15331927), in GBMs with a previous lower grade astrocytoma (Martinez et al., 2005; 15672285), and in giant cell GBM compared to classic GBM (Martinez et al., 2007; 17498554). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TERT", "Include": "true", "Alterations": {"Alteration": {"Name": "promoter _124C>T", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "promoter _124C>T"}}, "Interpretation": "Telomerase reverse transcriptase (TERT, or hTERT) is a catalytic subunit of the telomerase complex, which is required to maintain appropriate chromosomal length (Shay et al., 2011; 22015685). Activation of TERT is a hallmark of cancer, being detected in up to 80_90% of malignancies and absent in quiescent cells (Shay et al., 1997; 9282118, Kim et al., 1994; 7605428, Hanahan and Weinberg, 2000; 10647931). Mutations within the promoter region of TERT that confer enhanced TERT promoter activity have been reported in two hotspots, located at _124 bp and _146 bp upstream of the transcriptional start site (also termed C228T and C250T, respectively)(Horn et al., 2013; 23348503, Huang et al., 2014; 23348506, Vinagre et al., 2013; 23887589), as well as tandem mutations at positions \u2013124/\u2013125 bp and \u2013138/\u2013139 bp (Horn et al., 2013; 23348503). TERT promoter mutations have been reported in 51_59% of gliomas (Killela et al., 2013; 23530248, Killela et al., 2014; 24722048), most frequently in glioblastoma (GBM, 54_84%), gliosarcoma (81%), oligodendroglioma (78%), and historically in oligoastrocytomas (25_31%) but less frequently in lower grade astrocytomas (10_18%) and in only 1% of ependymomas (Nonoguchi et al., 2013; 23955565, Liu et al., 2013; 23603989, Koelsche et al., 2013; 24154961, Killela et al., 2013; 23530248, Killela et al., 2014; 24722048). In patients with glioblastoma (GBM), the prevalence of TERT promoter mutation is lower in pediatric primary GBM (11%) and adult secondary GBM (28%) compared with adult primary GBM (58_83%) (Nonoguchi et al., 2013; 23955565, Killela et al., 2013; 23530248). One study detected TERT promoter mutations in 78% (181/232) of IDH_wildtype GBM samples analyzed (Yan et al. 2020; DOI:10.1200/PO.19.00385). TERT promoter mutation has been shown to be significantly associated with increased TERT gene expression in astrocytoma, oligodendroglioma, and GBM (Arita et al., 2013; 23764841). TERT promoter mutations significantly associate with poor prognosis in patients with GBM, although this correlation may be due to the association with primary GBM as opposed to IDH_positive secondary GBM (Killela et al., 2013; 23530248, Nonoguchi et al., 2013; 23955565, Reitman et al., 2013; 24217890, Arita et al., 2013; 23764841). In the context of IDH_wildtype glioma, TERT mutations are associated with reduced OS (NCCN CNS Cancers Guidelines, v1.2022). Therapeutic options for targeting tumors with TERT mutations are limited, although a variety of approaches have been investigated, including immunotherapies using TERT as a tumor_associated antigen and antisense oligonucleotide_ or peptide_based therapies. TERT peptide vaccines showed limited anticancer efficacy in clinical trials (Zanetti et al., 2017; 27245281); however, in one preclinical study, the combination of a TERT peptide vaccine and anti_CTLA_4 therapy suppressed tumor growth (Duperret at al., 2018; 29249395). A Phase 2 study of the TERT inhibitor imetelstat for patients with advanced non_small cell lung cancer reported no improvement in PFS or OS (Chiappori et al., 2015; 25467017). TERT mutations are associated with 1p/19q co_deletion in oligodendrogliomas, and are highly recurrent in IDH/ATRX_wildtype glioblastoma (GBM) (NCCN CNS Cancers Guidelines, v1.2022)(Weller et al., 2020; 33293629). The presence of EGFR gene amplification or TERT promoter mutations are indicative of diffuse astrocytic glioma with molecular features of glioblastoma, WHO grade 4 in IDH1/2_wildtype tumors (NCCN CNS Cancers Guidelines, v1.2022) (Louis et al., 2021; 34185076).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "01", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "01"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Touat et al., 2020; 32322066, Kamiya_Matsuoka et al., 2019; ESMO Abstract 393O, Zhao et al., 2019; 30742119, Samstein et al., 2019; 30643254, Bouffet et al., 2016; 27001570, Johanns et al., 2016; 27683556, Lukas et al., 2018; 30073642). Glioblastoma (GBM) harbors a median TMB of 2.7 mutations per megabase (muts/Mb), and 4.2% of cases have high TMB (>20 muts/Mb)(FMI_Chalmers et al., 2017; 28420421). For pediatric patients, high TMB has been reported in a subset of high_grade gliomas, frequently in association with mutations in mismatch repair or proofreading genes and in TP53, whereas BRAF alterations or other oncogene fusions were observed more frequently in brain tumors harboring low TMB (Patel et al., 2020; 32386112, Johnson et al., 2017; 28912153). Increased TMB has been reported to correlate with higher tumor grade in glioma (Draaisma et al., 2015; 26699864) and glioblastoma (GBM) tissue samples with biallelic mismatch repair deficiency (bMMRD) (Bouffet et al., 2016; 27001570), as well as with shorter OS of patients with diffuse glioma (Wang et al., 2020; 32164609). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In glioma, a lack of association between TMB and clinical benefit from immune checkpoint inhibitors has been reported (Kamiya_Matsuoka et al., 2019; ESMO Abstract 393O, Zhao et al., 2019; 30742119, Samstein et al., 2019; 30643254, Touat et al., 2020; 32322066). However, multiple case studies have reported that patients with ultramutated gliomas driven by POLE mutations have benefited from treatment with anti_PD_1 (Bouffet et al., 2016; 27001570, Johanns et al., 2016; 27683556) or anti_PD_L1 (Lukas et al., 2018; 30073642) therapies. Therefore, although increased TMB alone may not be a strong biomarker for PD_1 or PD_L1 inhibitors in this cancer type, these agents may have efficacy for patients with glioma harboring both high TMB and POLE mutation.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "FBXW7", "Alteration": "R465H", "Title": "Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event", "StudyPhase": "PHASE 2", "Target": "EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6", "Locations": "Shanghai (China)", "NCTID": "NCT03239015", "Note": "Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "FBXW7", "Alteration": "R465H", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "FBXW7", "Alteration": "R465H", "Title": "A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "mTOR", "Locations": "Tianjin (China)", "NCTID": "NCT05125523", "Note": "Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "FBXW7", "Alteration": "R465H", "Title": "NCT Neuro Master Match _ N\u00b2M\u00b2 (NOA_20)", "StudyPhase": "PHASE 1/2", "Target": "ALK, RET, CDK4, CDK6, mTOR, MDM2, PD_L1, SMO", "Locations": "Berlin (Germany), Dresden (Germany), Regensburg (Germany), Bochum (Germany), Frankfurt am Main (Germany), Essen (Germany), Mainz (Germany), Heidelberg (Germany), Cologne (Germany), Mannheim (Germany)", "NCTID": "NCT03158389", "Note": "Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "FBXW7", "Alteration": "R465H", "Title": "A Phase 1 Trial of Vandetanib (a Multi_kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer", "StudyPhase": "PHASE 1", "Target": "mTOR, EGFR, SRC, RET, VEGFRs", "Locations": "Texas", "NCTID": "NCT01582191", "Note": "Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "FBXW7", "Alteration": "R465H", "Title": "Combination Chemotherapy and Bevacizumab With the NovoTTF_100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer", "StudyPhase": "PHASE 1", "Target": "VEGFA, mTOR", "Locations": "Texas", "NCTID": "NCT03203525", "Note": "Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "MTAP", "Alteration": "loss", "Title": "Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion", "StudyPhase": "PHASE 1/2", "Target": "PRMT5_MTA", "Locations": "Colorado, Massachusetts, New York, Tennessee, Texas", "NCTID": "NCT05245500", "Note": "MTAP loss may predict sensitivity to MAT2A inhibitors, or to inhibitors that target PRMT5 when in complex with MTA.", "Include": "true"}, {"Gene": "PDGFRA", "Alteration": "D842Vdeletion exons 8_9", "Title": "A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma", "StudyPhase": "PHASE 2/3", "Target": "BRAF, VEGFRs, RET, KIT", "Locations": "Utah, Michigan, New York", "NCTID": "NCT03970447", "Note": "PDGFRA activating mutations may predict sensitivity to certain PDGFRA_targeted therapies. PDGFRA D842V predicts resistance to imatinib and sunitinib and may confer reduced sensitivity to regorafenib or ponatinib in the context of FIP1L1_PDGFRA fusion. Therefore, it is unclear whether dasatinib or nilotinib may provide clinical benefit for patients with PDGFRA D842V and whether sorafenib may be effective against PDGFRA_rearranged tumors with the D842V mutation. On the basis of limited clinical and preclinical evidence, D842V in combination with co_occurring mutations Y676C, G652E, QGPins, V658A, T674R, or G680R may have reduced sensitivity to avapritinib.", "Include": "true"}, {"Gene": "PDGFRA", "Alteration": "D842Vdeletion exons 8_9", "Title": "The Finnish National Study to Facilitate Patient Access to Targeted Anti_cancer Drugs", "StudyPhase": "PHASE 2", "Target": "BRAF, VEGFRs, RET, KIT, ERBB2, TRKB, ALK, TRKC, ROS1, TRKA, SMO, PD_L1, MEK, CDK4, CDK6", "Locations": "Kuopio (Finland), Helsinki (Finland), Tampere (Finland), Turku (Finland)", "NCTID": "NCT05159245", "Note": "PDGFRA activating mutations may predict sensitivity to certain PDGFRA_targeted therapies. PDGFRA D842V predicts resistance to imatinib and sunitinib and may confer reduced sensitivity to regorafenib or ponatinib in the context of FIP1L1_PDGFRA fusion. Therefore, it is unclear whether dasatinib or nilotinib may provide clinical benefit for patients with PDGFRA D842V and whether sorafenib may be effective against PDGFRA_rearranged tumors with the D842V mutation. On the basis of limited clinical and preclinical evidence, D842V in combination with co_occurring mutations Y676C, G652E, QGPins, V658A, T674R, or G680R may have reduced sensitivity to avapritinib.", "Include": "true"}, {"Gene": "PDGFRA", "Alteration": "D842Vdeletion exons 8_9", "Title": "Avapritinib for the Treatment of CKIT or PDGFRA Mutation_Positive Locally Advanced or Metastatic Malignant Solid Tumors", "StudyPhase": "PHASE 2", "Target": "KIT, PDGFRA", "Locations": "Texas", "NCTID": "NCT04771520", "Note": "PDGFRA activating mutations may predict sensitivity to certain PDGFRA_targeted therapies. PDGFRA D842V predicts resistance to imatinib and sunitinib and may confer reduced sensitivity to regorafenib or ponatinib in the context of FIP1L1_PDGFRA fusion. Therefore, it is unclear whether dasatinib or nilotinib may provide clinical benefit for patients with PDGFRA D842V and whether sorafenib may be effective against PDGFRA_rearranged tumors with the D842V mutation. On the basis of limited clinical and preclinical evidence, D842V in combination with co_occurring mutations Y676C, G652E, QGPins, V658A, T674R, or G680R may have reduced sensitivity to avapritinib.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "K342N", "Title": "Study of AZD5305 as Monotherapy and in Combination With Anti_cancer Agents in Patients With Advanced Solid Malignancies", "StudyPhase": "PHASE 1/2", "Target": "ERBB2, TROP2, PARP", "Locations": "Shanghai (China), Seoul (Korea, Republic of), Chongqing (China), Chuo_ku (Japan), Koto_ku (Japan), Melbourne (Australia), Warszawa (Poland), Gdynia (Poland), Grzepnica (Poland), Budapest (Hungary)", "NCTID": "NCT04644068", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "K342N", "Title": "A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Metastatic Solid Tumors.", "StudyPhase": "PHASE 1", "Target": "AKTs", "Locations": "Shanghai City (China)", "NCTID": "NCT04341259", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "K342N", "Title": "Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP, PD_L1", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom)", "NCTID": "NCT02264678", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "K342N", "Title": "Talazoparib _ Carboplatin for Recurrent High_grade Glioma With DDRd", "StudyPhase": "PHASE 2", "Target": "PARP", "Locations": "Hong Kong (Hong Kong)", "NCTID": "NCT04740190", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "K342N", "Title": "AZD8186 and Paclitaxel in Advanced Gastric Cancer", "StudyPhase": "PHASE 1/2", "Target": "PI3K_beta", "Locations": "Seongnam_si (Korea, Republic of)", "NCTID": "NCT04001569", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "K342N", "Title": "Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)", "StudyPhase": "PHASE 1/2", "Target": "XPO1, PARP", "Locations": "Singapore (Singapore)", "NCTID": "NCT05035745", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "K342N", "Title": "Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies", "StudyPhase": "PHASE 1", "Target": "PARP, AKTs, PD_L1", "Locations": "Singapore (Singapore)", "NCTID": "NCT03772561", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "K342N", "Title": "Phase 0/2 Study of Pamiparib in Newly Diagnosed and rGBM", "StudyPhase": "PHASE null", "Target": "PARP", "Locations": "Arizona", "NCTID": "NCT04614909", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "K342N", "Title": "Trial of Niraparib in Participants With Newly_diagnosed Glioblastoma and Recurrent Glioma", "StudyPhase": "PHASE null", "Target": "PARP", "Locations": "Arizona", "NCTID": "NCT05076513", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "K342N", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "18483217", "FullCitation": "Andrae J, et al. Genes Dev. (2008) pmid: 18483217", "Include": "true"}, {"number": "1", "ReferenceId": "15175998", "FullCitation": "Semin. Oncol. (2004) pmid: 15175998", "Include": "true"}, {"number": "2", "ReferenceId": "22718859", "FullCitation": "Cassier PA, et al. Clin. Cancer Res. (2012) pmid: 22718859", "Include": "true"}, {"number": "3", "ReferenceId": "15685537", "FullCitation": "Debiec_Rychter M, et al. Gastroenterology (2005) pmid: 15685537", "Include": "true"}, {"number": "4", "ReferenceId": "14645423", "FullCitation": "Heinrich MC, et al. J. Clin. Oncol. (2003) pmid: 14645423", "Include": "true"}, {"number": "5", "ReferenceId": "18955451", "FullCitation": "Heinrich MC, et al. J. Clin. Oncol. (2008) pmid: 18955451", "Include": "true"}, {"number": "6", "ReferenceId": "18955458", "FullCitation": "Heinrich MC, et al. J. Clin. Oncol. (2008) pmid: 18955458", "Include": "true"}, {"number": "7", "ReferenceId": "22665524", "FullCitation": "Heinrich MC, et al. Mol. Cancer Ther. (2012) pmid: 22665524", "Include": "true"}, {"number": "8", "ReferenceId": "22745105", "FullCitation": "Heinrich MC, et al. Clin. Cancer Res. (2012) pmid: 22745105", "Include": "true"}, {"number": "9", "ReferenceId": "26130666", "FullCitation": "Yoo C, et al. Cancer Res Treat (2016) pmid: 26130666", "Include": "true"}, {"number": "10", "ReferenceId": "30389923", "FullCitation": "Ip CKM, et al. Nat Commun (2018) pmid: 30389923", "Include": "true"}, {"number": "11", "ReferenceId": "18794084", "FullCitation": "Dewaele B, et al. Clin. Cancer Res. (2008) pmid: 18794084", "Include": "true"}, {"number": "12", "ReferenceId": "23970477", "FullCitation": "Paugh BS, et al. Cancer Res. (2013) pmid: 23970477", "Include": "true"}, {"number": "13", "ReferenceId": "19212337", "FullCitation": "Lierman E, et al. Leukemia (2009) pmid: 19212337", "Include": "true"}, {"number": "14", "ReferenceId": "24407160", "FullCitation": "Sadovnik I, et al. Exp. Hematol. (2014) pmid: 24407160", "Include": "true"}, {"number": "15", "ReferenceId": "17087936", "FullCitation": "Weisberg E, et al. Gastroenterology (2006) pmid: 17087936", "Include": "true"}, {"number": "16", "ReferenceId": "20972453", "FullCitation": "von Bubnoff N, et al. Oncogene (2011) pmid: 20972453", "Include": "true"}, {"number": "17", "ReferenceId": "34343033", "FullCitation": "Kang YK, et al. J Clin Oncol (2021) pmid: 34343033", "Include": "true"}, {"number": "18", "ReferenceId": "32615108", "FullCitation": "Heinrich MC, et al. Lancet Oncol (2020) pmid: 32615108", "Include": "true"}, {"number": "19", "ReferenceId": "29093181", "FullCitation": "Evans EK, et al. Sci Transl Med (2017) pmid: 29093181", "Include": "true"}, {"number": "20", "ReferenceId": "32972961", "FullCitation": "Grunewald S, et al. Cancer Discov (2020) pmid: 32972961", "Include": "true"}, {"number": "21", "ReferenceId": "12569364", "FullCitation": "Clarke ID, et al. Oncogene (2003) pmid: 12569364", "Include": "true"}, {"number": "22", "ReferenceId": "20889717", "FullCitation": "Ozawa T, et al. Genes Dev. (2010) pmid: 20889717", "Include": "true"}, {"number": "23", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "24", "ReferenceId": "24120142", "FullCitation": "Brennan CW, et al. Cell (2013) pmid: 24120142", "Include": "true"}, {"number": "25", "ReferenceId": "18772890", "FullCitation": "Nature (2008) pmid: 18772890", "Include": "true"}, {"number": "26", "ReferenceId": "29625048", "FullCitation": "Hoadley KA, et al. Cell (2018) pmid: 29625048", "Include": "true"}, {"number": "27", "ReferenceId": "29596782", "FullCitation": "Ellrott K, et al. Cell Syst (2018) pmid: 29596782", "Include": "true"}, {"number": "28", "ReferenceId": "29622463", "FullCitation": "Taylor AM, et al. Cancer Cell (2018) pmid: 29622463", "Include": "true"}, {"number": "29", "ReferenceId": "29617662", "FullCitation": "Gao Q, et al. Cell Rep (2018) pmid: 29617662", "Include": "true"}, {"number": "30", "ReferenceId": "29625055", "FullCitation": "Liu J, et al. Cell (2018) pmid: 29625055", "Include": "true"}, {"number": "31", "ReferenceId": "29625050", "FullCitation": "Sanchez_Vega F, et al. Cell (2018) pmid: 29625050", "Include": "true"}, {"number": "32", "ReferenceId": "29888103", "FullCitation": "Song K, et al. Am J Cancer Res (2018) pmid: 29888103", "Include": "true"}, {"number": "33", "ReferenceId": "23074200", "FullCitation": "Alentorn A, et al. Neuro_oncology (2012) pmid: 23074200", "Include": "true"}, {"number": "34", "ReferenceId": "23412337", "FullCitation": "Sottoriva A, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 23412337", "Include": "true"}, {"number": "35", "ReferenceId": "23438035", "FullCitation": "Phillips JJ, et al. Brain Pathol. (2013) pmid: 23438035", "Include": "true"}, {"number": "36", "ReferenceId": "22806436", "FullCitation": "Arefi M, et al. Int. J. Hematol. (2012) pmid: 22806436", "Include": "true"}, {"number": "37", "ReferenceId": "17666373", "FullCitation": "Baccarani M, et al. Haematologica (2007) pmid: 17666373", "Include": "true"}, {"number": "38", "ReferenceId": "25658984", "FullCitation": "Chalmers ZR, et al. Blood Cancer J (2015) pmid: 25658984", "Include": "true"}, {"number": "39", "ReferenceId": "12660384", "FullCitation": "Cools J, et al. N. Engl. J. Med. (2003) pmid: 12660384", "Include": "true"}, {"number": "40", "ReferenceId": "17555450", "FullCitation": "Curtis CE, et al. Br. J. Haematol. (2007) pmid: 17555450", "Include": "true"}, {"number": "41", "ReferenceId": "15010069", "FullCitation": "Debiec_Rychter M, et al. Eur. J. Cancer (2004) pmid: 15010069", "Include": "true"}, {"number": "42", "ReferenceId": "20473908", "FullCitation": "Dileo P, et al. Int. J. Cancer (2011) pmid: 20473908", "Include": "true"}, {"number": "43", "ReferenceId": "24638008", "FullCitation": "Fanta PT, et al. J. Clin. Oncol. (2015) pmid: 24638008", "Include": "true"}, {"number": "44", "ReferenceId": "16406018", "FullCitation": "Florian S, et al. Leuk. Res. (2006) pmid: 16406018", "Include": "true"}, {"number": "45", "ReferenceId": "27051816", "FullCitation": "Frenard C, et al. JAAD Case Rep (2016) pmid: 27051816", "Include": "true"}, {"number": "46", "ReferenceId": "12808148", "FullCitation": "Griffin JH, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12808148", "Include": "true"}, {"number": "47", "ReferenceId": "19120352", "FullCitation": "Helbig G, et al. Br. J. Haematol. (2009) pmid: 19120352", "Include": "true"}, {"number": "48", "ReferenceId": "24009127", "FullCitation": "Helbig G, et al. Am. J. Hematol. (2014) pmid: 24009127", "Include": "true"}, {"number": "49", "ReferenceId": "21093052", "FullCitation": "Hus M, et al. Leuk. Res. (2011) pmid: 21093052", "Include": "true"}, {"number": "50", "ReferenceId": "20303172", "FullCitation": "Ikezoe T, et al. Leuk. Res. (2010) pmid: 20303172", "Include": "true"}, {"number": "51", "ReferenceId": "19735261", "FullCitation": "Intermesoli T, et al. Br. J. Haematol. (2009) pmid: 19735261", "Include": "true"}, {"number": "52", "ReferenceId": "19013640", "FullCitation": "Jain N, et al. Leuk. Res. (2009) pmid: 19013640", "Include": "true"}, {"number": "53", "ReferenceId": "17299092", "FullCitation": "Jovanovic JV, et al. Blood (2007) pmid: 17299092", "Include": "true"}, {"number": "54", "ReferenceId": "22150077", "FullCitation": "Kang HJ, et al. Acta Oncol (2012) pmid: 22150077", "Include": "true"}, {"number": "55", "ReferenceId": "14504092", "FullCitation": "Klion AD, et al. Blood (2004) pmid: 14504092", "Include": "true"}, {"number": "56", "ReferenceId": "19192229", "FullCitation": "Kobayashi M, et al. Respirology (2009) pmid: 19192229", "Include": "true"}, {"number": "57", "ReferenceId": "24635438", "FullCitation": "Koc\u00e1kov\u00e1 I, et al. Klin Onkol (2014) pmid: 24635438", "Include": "true"}, {"number": "58", "ReferenceId": "18950453", "FullCitation": "Metzgeroth G, et al. Br. J. Haematol. (2008) pmid: 18950453", "Include": "true"}, {"number": "59", "ReferenceId": "22645636", "FullCitation": "Murayama Y, et al. World J Gastrointest Oncol (2012) pmid: 22645636", "Include": "true"}, {"number": "60", "ReferenceId": "19910029", "FullCitation": "Ogbogu PU, et al. J. Allergy Clin. Immunol. (2009) pmid: 19910029", "Include": "true"}, {"number": "61", "ReferenceId": "16856885", "FullCitation": "Ohnishi H, et al. Br. J. Haematol. (2006) pmid: 16856885", "Include": "true"}, {"number": "62", "ReferenceId": "12842979", "FullCitation": "Pardanani A, et al. Blood (2003) pmid: 12842979", "Include": "true"}, {"number": "63", "ReferenceId": "15284118", "FullCitation": "Pardanani A, et al. Blood (2004) pmid: 15284118", "Include": "true"}, {"number": "64", "ReferenceId": "27120808", "FullCitation": "Qu SQ, et al. Oncotarget (2016) pmid: 27120808", "Include": "true"}, {"number": "65", "ReferenceId": "16498388", "FullCitation": "Score J, et al. Leukemia (2006) pmid: 16498388", "Include": "true"}, {"number": "66", "ReferenceId": "24669761", "FullCitation": "Shah S, et al. J Hematol Oncol (2014) pmid: 24669761", "Include": "true"}, {"number": "67", "ReferenceId": "26319757", "FullCitation": "Sugimoto Y, et al. Cancer Genet (2015) pmid: 26319757", "Include": "true"}, {"number": "68", "ReferenceId": "20609486", "FullCitation": "Volz HC, et al. Int. J. Cardiol. (2011) pmid: 20609486", "Include": "true"}, {"number": "69", "ReferenceId": "15618966", "FullCitation": "von Bubnoff N, et al. Leukemia (2005) pmid: 15618966", "Include": "true"}, {"number": "70", "ReferenceId": "16845659", "FullCitation": "Walz C, et al. Genes Chromosomes Cancer (2006) pmid: 16845659", "Include": "true"}, {"number": "71", "ReferenceId": "23157309", "FullCitation": "Al_Riyami AZ, et al. Leuk. Lymphoma (2013) pmid: 23157309", "Include": "true"}, {"number": "72", "ReferenceId": "16645167", "FullCitation": "Lierman E, et al. Blood (2006) pmid: 16645167", "Include": "true"}, {"number": "73", "ReferenceId": "21818111", "FullCitation": "Metzgeroth G, et al. Leukemia (2012) pmid: 21818111", "Include": "true"}, {"number": "74", "ReferenceId": "22294526", "FullCitation": "Roubaud G, et al. Ann. Oncol. (2012) pmid: 22294526", "Include": "true"}, {"number": "75", "ReferenceId": "24057647", "FullCitation": "Hochhaus A, et al. J. Cancer Res. Clin. Oncol. (2013) pmid: 24057647", "Include": "true"}, {"number": "76", "ReferenceId": "20832858", "FullCitation": "Tabouret E, et al. Leuk. Res. (2011) pmid: 20832858", "Include": "true"}, {"number": "77", "ReferenceId": "26396737", "FullCitation": "Brohl AS, et al. Clin Sarcoma Res (2015) pmid: 26396737", "Include": "true"}, {"number": "78", "ReferenceId": "28031906", "FullCitation": "Grellety T, et al. Future Sci OA (2015) pmid: 28031906", "Include": "true"}, {"number": "79", "ReferenceId": "25905001", "FullCitation": "Koll\u00e0r A, et al. Clin Sarcoma Res (2014) pmid: 25905001", "Include": "true"}, {"number": "80", "ReferenceId": "16638875", "FullCitation": "Prenen H, et al. Clin. Cancer Res. (2006) pmid: 16638875", "Include": "true"}, {"number": "81", "ReferenceId": "18987650", "FullCitation": "Score J, et al. Leukemia (2009) pmid: 18987650", "Include": "true"}, {"number": "82", "ReferenceId": "19466970", "FullCitation": "Sorour Y, et al. Br. J. Haematol. (2009) pmid: 19466970", "Include": "true"}, {"number": "83", "ReferenceId": "22301675", "FullCitation": "Lierman E, et al. Leukemia (2012) pmid: 22301675", "Include": "true"}, {"number": "84", "ReferenceId": "11237521", "FullCitation": "Simpson L, et al. Exp. Cell Res. (2001) pmid: 11237521", "Include": "true"}, {"number": "85", "ReferenceId": "12857747", "FullCitation": "Campbell RB, et al. J. Biol. Chem. (2003) pmid: 12857747", "Include": "true"}, {"number": "86", "ReferenceId": "21828076", "FullCitation": "Rodr\u00edguez_Escudero I, et al. Hum. Mol. Genet. (2011) pmid: 21828076", "Include": "true"}, {"number": "87", "ReferenceId": "23475934", "FullCitation": "He X, et al. Cancer Res. (2013) pmid: 23475934", "Include": "true"}, {"number": "88", "ReferenceId": "10866302", "FullCitation": "Han SY, et al. Cancer Res. (2000) pmid: 10866302", "Include": "true"}, {"number": "89", "ReferenceId": "9811831", "FullCitation": "Myers MP, et al. Proc. Natl. Acad. Sci. U.S.A. (1998) pmid: 9811831", "Include": "true"}, {"number": "90", "ReferenceId": "24498881", "FullCitation": "Pradella LM, et al. BMC Cancer (2014) pmid: 24498881", "Include": "true"}, {"number": "91", "ReferenceId": "21536651", "FullCitation": "Kim JS, et al. Mol. Cell. Biol. (2011) pmid: 21536651", "Include": "true"}, {"number": "92", "ReferenceId": "17213812", "FullCitation": "Denning G, et al. Oncogene (2007) pmid: 17213812", "Include": "true"}, {"number": "93", "ReferenceId": "16619501", "FullCitation": "Hlobilkova A, et al. Anticancer Res. () pmid: 16619501", "Include": "true"}, {"number": "94", "ReferenceId": "20718038", "FullCitation": "Redfern RE, et al. Protein Sci. (2010) pmid: 20718038", "Include": "true"}, {"number": "95", "ReferenceId": "22505997", "FullCitation": "Shenoy S, et al. PLoS ONE (2012) pmid: 22505997", "Include": "true"}, {"number": "96", "ReferenceId": "19329485", "FullCitation": "Wang Y, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19329485", "Include": "true"}, {"number": "97", "ReferenceId": "16829519", "FullCitation": "Okumura K, et al. J. Biol. Chem. (2006) pmid: 16829519", "Include": "true"}, {"number": "98", "ReferenceId": "10555148", "FullCitation": "Lee JO, et al. Cell (1999) pmid: 10555148", "Include": "true"}, {"number": "99", "ReferenceId": "9635567", "FullCitation": "Maxwell GL, et al. Cancer Res. (1998) pmid: 9635567", "Include": "true"}, {"number": "100", "ReferenceId": "9865913", "FullCitation": "Risinger JI, et al. Clin. Cancer Res. (1998) pmid: 9865913", "Include": "true"}, {"number": "101", "ReferenceId": "11051241", "FullCitation": "Kato H, et al. Clin. Cancer Res. (2000) pmid: 11051241", "Include": "true"}, {"number": "102", "ReferenceId": "22891331", "FullCitation": "Fenton TR, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22891331", "Include": "true"}, {"number": "103", "ReferenceId": "23066114", "FullCitation": "Ngeow J, et al. J. Clin. Endocrinol. Metab. (2012) pmid: 23066114", "Include": "true"}, {"number": "104", "ReferenceId": "19457929", "FullCitation": "Lobo GP, et al. Hum. Mol. Genet. (2009) pmid: 19457929", "Include": "true"}, {"number": "105", "ReferenceId": "23995781", "FullCitation": "Liu J, et al. Oncogene (2014) pmid: 23995781", "Include": "true"}, {"number": "106", "ReferenceId": "11395408", "FullCitation": "Maehama T, et al. Annu. Rev. Biochem. (2001) pmid: 11395408", "Include": "true"}, {"number": "107", "ReferenceId": "10807691", "FullCitation": "De Vivo I, et al. J. Med. Genet. (2000) pmid: 10807691", "Include": "true"}, {"number": "108", "ReferenceId": "10051603", "FullCitation": "Ramaswamy S, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10051603", "Include": "true"}, {"number": "109", "ReferenceId": "15988030", "FullCitation": "Liu JL, et al. Mol. Cell. Biol. (2005) pmid: 15988030", "Include": "true"}, {"number": "110", "ReferenceId": "15026806", "FullCitation": "Karoui M, et al. Br. J. Cancer (2004) pmid: 15026806", "Include": "true"}, {"number": "111", "ReferenceId": "25875300", "FullCitation": "Gil A, et al. PLoS ONE (2015) pmid: 25875300", "Include": "true"}, {"number": "112", "ReferenceId": "9823298", "FullCitation": "Furnari FB, et al. Cancer Res. (1998) pmid: 9823298", "Include": "true"}, {"number": "113", "ReferenceId": "25527629", "FullCitation": "Spinelli L, et al. J. Med. Genet. (2015) pmid: 25527629", "Include": "true"}, {"number": "114", "ReferenceId": "29706633", "FullCitation": "Mingo J, et al. Eur. J. Hum. Genet. (2018) pmid: 29706633", "Include": "true"}, {"number": "115", "ReferenceId": "20538496", "FullCitation": "Wang Q, et al. J. Mol. Graph. Model. (2010) pmid: 20538496", "Include": "true"}, {"number": "116", "ReferenceId": "17942903", "FullCitation": "Andr\u00e9s_Pons A, et al. Cancer Res. (2007) pmid: 17942903", "Include": "true"}, {"number": "117", "ReferenceId": "15805158", "FullCitation": "Butler MG, et al. J. Med. Genet. (2005) pmid: 15805158", "Include": "true"}, {"number": "118", "ReferenceId": "10468583", "FullCitation": "Georgescu MM, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10468583", "Include": "true"}, {"number": "119", "ReferenceId": "12085208", "FullCitation": "Staal FJ, et al. Br. J. Cancer (2002) pmid: 12085208", "Include": "true"}, {"number": "120", "ReferenceId": "24292679", "FullCitation": "Nguyen HN, et al. Oncogene (2014) pmid: 24292679", "Include": "true"}, {"number": "121", "ReferenceId": "19114656", "FullCitation": "Rahdar M, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19114656", "Include": "true"}, {"number": "122", "ReferenceId": "12808147", "FullCitation": "Das S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12808147", "Include": "true"}, {"number": "123", "ReferenceId": "18498243", "FullCitation": "Wang X, et al. Biochem. J. (2008) pmid: 18498243", "Include": "true"}, {"number": "124", "ReferenceId": "15951562", "FullCitation": "Valiente M, et al. J. Biol. Chem. (2005) pmid: 15951562", "Include": "true"}, {"number": "125", "ReferenceId": "25263454", "FullCitation": "Nguyen HN, et al. Oncogene (2015) pmid: 25263454", "Include": "true"}, {"number": "126", "ReferenceId": "32704382", "FullCitation": "Shan L, et al. Cell Discov (2020) pmid: 32704382", "Include": "true"}, {"number": "127", "ReferenceId": "10096247", "FullCitation": "Zhou XP, et al. Int. J. Cancer (1999) pmid: 10096247", "Include": "true"}, {"number": "128", "ReferenceId": "9331072", "FullCitation": "Rasheed BK, et al. Cancer Res. (1997) pmid: 9331072", "Include": "true"}, {"number": "129", "ReferenceId": "10188904", "FullCitation": "Davies MP, et al. Br. J. Cancer (1999) pmid: 10188904", "Include": "true"}, {"number": "130", "ReferenceId": "11504770", "FullCitation": "Smith JS, et al. J. Natl. Cancer Inst. (2001) pmid: 11504770", "Include": "true"}, {"number": "131", "ReferenceId": "9796977", "FullCitation": "Lin H, et al. Clin. Cancer Res. (1998) pmid: 9796977", "Include": "true"}, {"number": "132", "ReferenceId": "10560660", "FullCitation": "Schmidt EE, et al. J. Neuropathol. Exp. Neurol. (1999) pmid: 10560660", "Include": "true"}, {"number": "133", "ReferenceId": "17974913", "FullCitation": "Furnari FB, et al. Genes Dev. (2007) pmid: 17974913", "Include": "true"}, {"number": "134", "ReferenceId": "26061751", "FullCitation": "Cancer Genome Atlas Research Network, et al. N. Engl. J. Med. (2015) pmid: 26061751", "Include": "true"}, {"number": "135", "ReferenceId": "10213484", "FullCitation": "Sano T, et al. Cancer Res. (1999) pmid: 10213484", "Include": "true"}, {"number": "136", "ReferenceId": "21134002", "FullCitation": "Srividya MR, et al. Neuropathology (2011) pmid: 21134002", "Include": "true"}, {"number": "137", "ReferenceId": "20085938", "FullCitation": "Courtney KD, et al. J. Clin. Oncol. (2010) pmid: 20085938", "Include": "true"}, {"number": "138", "ReferenceId": "27672108", "FullCitation": "Patnaik A, et al. Ann. Oncol. (2016) pmid: 27672108", "Include": "true"}, {"number": "139", "ReferenceId": "28220839", "FullCitation": "Milella M, et al. Sci Rep (2017) pmid: 28220839", "Include": "true"}, {"number": "140", "ReferenceId": "15998902", "FullCitation": "Galanis E, et al. J. Clin. Oncol. (2005) pmid: 15998902", "Include": "true"}, {"number": "141", "ReferenceId": "19018475", "FullCitation": "Kreisl TN, et al. J. Neurooncol. (2009) pmid: 19018475", "Include": "true"}, {"number": "142", "ReferenceId": "22160854", "FullCitation": "Mason WP, et al. Invest New Drugs (2012) pmid: 22160854", "Include": "true"}, {"number": "143", "ReferenceId": "20049735", "FullCitation": "Mendes_Pereira AM, et al. EMBO Mol Med (2009) pmid: 20049735", "Include": "true"}, {"number": "144", "ReferenceId": "23881923", "FullCitation": "Shen Y, et al. Clin. Cancer Res. (2013) pmid: 23881923", "Include": "true"}, {"number": "145", "ReferenceId": "23565244", "FullCitation": "Chatterjee P, et al. PLoS ONE (2013) pmid: 23565244", "Include": "true"}, {"number": "146", "ReferenceId": "26905328", "FullCitation": "McCormick A, et al. Int. J. Gynecol. Cancer (2016) pmid: 26905328", "Include": "true"}, {"number": "147", "ReferenceId": "21468130", "FullCitation": "Forster MD, et al. Nat Rev Clin Oncol (2011) pmid: 21468130", "Include": "true"}, {"number": "148", "ReferenceId": "33242536", "FullCitation": "Eikesdal HP, et al. Ann Oncol (2021) pmid: 33242536", "Include": "true"}, {"number": "149", "ReferenceId": "33970096", "FullCitation": "Pan M, et al. Perm J (2021) pmid: 33970096", "Include": "true"}, {"number": "150", "ReferenceId": "23810788", "FullCitation": "Sandhu SK, et al. Lancet Oncol. (2013) pmid: 23810788", "Include": "true"}, {"number": "151", "ReferenceId": "32988624", "FullCitation": "Romero I, et al. Gynecol Oncol (2020) pmid: 32988624", "Include": "true"}, {"number": "152", "ReferenceId": "18781191", "FullCitation": "Blumenthal GM, et al. Eur. J. Hum. Genet. (2008) pmid: 18781191", "Include": "true"}, {"number": "153", "ReferenceId": "18794875", "FullCitation": "Orloff MS, et al. Oncogene (2008) pmid: 18794875", "Include": "true"}, {"number": "154", "ReferenceId": "17167516", "FullCitation": "Zbuk KM, et al. Nat. Rev. Cancer (2007) pmid: 17167516", "Include": "true"}, {"number": "155", "ReferenceId": "27479139", "FullCitation": "Limm K, et al. PLoS ONE (2016) pmid: 27479139", "Include": "true"}, {"number": "156", "ReferenceId": "25387827", "FullCitation": "Tang B, et al. G3 (Bethesda) (2014) pmid: 25387827", "Include": "true"}, {"number": "157", "ReferenceId": "21356366", "FullCitation": "Kirovski G, et al. Am. J. Pathol. (2011) pmid: 21356366", "Include": "true"}, {"number": "158", "ReferenceId": "23265702", "FullCitation": "Limm K, et al. Eur. J. Cancer (2013) pmid: 23265702", "Include": "true"}, {"number": "159", "ReferenceId": "19097084", "FullCitation": "Stevens AP, et al. J. Cell. Biochem. (2009) pmid: 19097084", "Include": "true"}, {"number": "160", "ReferenceId": "27068473", "FullCitation": "Marjon K, et al. Cell Rep (2016) pmid: 27068473", "Include": "true"}, {"number": "161", "ReferenceId": "26912361", "FullCitation": "Mavrakis KJ, et al. Science (2016) pmid: 26912361", "Include": "true"}, {"number": "162", "ReferenceId": "26912360", "FullCitation": "Kryukov GV, et al. Science (2016) pmid: 26912360", "Include": "true"}, {"number": "163", "ReferenceId": "25087184", "FullCitation": "Limm K, et al. Eur. J. Cancer (2014) pmid: 25087184", "Include": "true"}, {"number": "164", "ReferenceId": "27929028", "FullCitation": "Wei R, et al. Sci Rep (2016) pmid: 27929028", "Include": "true"}, {"number": "165", "ReferenceId": "27556634", "FullCitation": "Zhao M, et al. BMC Genomics (2016) pmid: 27556634", "Include": "true"}, {"number": "166", "ReferenceId": "19887491", "FullCitation": "Huang HY, et al. Clin. Cancer Res. (2009) pmid: 19887491", "Include": "true"}, {"number": "167", "ReferenceId": "16778103", "FullCitation": "Marc\u00e9 S, et al. Clin. Cancer Res. (2006) pmid: 16778103", "Include": "true"}, {"number": "168", "ReferenceId": "20500769", "FullCitation": "Meyer S, et al. Exp. Dermatol. (2010) pmid: 20500769", "Include": "true"}, {"number": "169", "ReferenceId": "16618867", "FullCitation": "Wild PJ, et al. Arch Dermatol (2006) pmid: 16618867", "Include": "true"}, {"number": "170", "ReferenceId": "21412930", "FullCitation": "Kim J, et al. Genes Chromosomes Cancer (2011) pmid: 21412930", "Include": "true"}, {"number": "171", "ReferenceId": "25426549", "FullCitation": "Li CF, et al. Oncotarget (2014) pmid: 25426549", "Include": "true"}, {"number": "172", "ReferenceId": "26656376", "FullCitation": "He HL, et al. Medicine (Baltimore) (2015) pmid: 26656376", "Include": "true"}, {"number": "173", "ReferenceId": "24969958", "FullCitation": "Su CY, et al. Eur J Surg Oncol (2014) pmid: 24969958", "Include": "true"}, {"number": "174", "ReferenceId": "16818274", "FullCitation": "Mirebeau D, et al. Haematologica (2006) pmid: 16818274", "Include": "true"}, {"number": "175", "ReferenceId": "26088413", "FullCitation": "Becker AP, et al. Pathobiology (2015) pmid: 26088413", "Include": "true"}, {"number": "176", "ReferenceId": "27433286", "FullCitation": "Snezhkina AV, et al. Oxid Med Cell Longev (2016) pmid: 27433286", "Include": "true"}, {"number": "177", "ReferenceId": "26910893", "FullCitation": "Bistulfi G, et al. Oncotarget (2016) pmid: 26910893", "Include": "true"}, {"number": "178", "ReferenceId": "25407435", "FullCitation": "Antonopoulou K, et al. J. Invest. Dermatol. (2015) pmid: 25407435", "Include": "true"}, {"number": "179", "ReferenceId": "23816148", "FullCitation": "Maccioni L, et al. BMC Cancer (2013) pmid: 23816148", "Include": "true"}, {"number": "180", "ReferenceId": "26635288", "FullCitation": "Hyland PL, et al. Int J Epidemiol (2016) pmid: 26635288", "Include": "true"}, {"number": "181", "ReferenceId": "27960044", "FullCitation": "Lin X, et al. Cancer Sci. (2017) pmid: 27960044", "Include": "true"}, {"number": "182", "ReferenceId": "27994653", "FullCitation": "Zhi L, et al. J Cancer (2016) pmid: 27994653", "Include": "true"}, {"number": "183", "ReferenceId": "23361049", "FullCitation": "Gu F, et al. Br. J. Cancer (2013) pmid: 23361049", "Include": "true"}, {"number": "184", "ReferenceId": "33450196", "FullCitation": "Kalev P, et al. Cancer Cell (2021) pmid: 33450196", "Include": "true"}, {"number": "185", "ReferenceId": "31350521", "FullCitation": "Guccione E, et al. Nat. Rev. Mol. Cell Biol. (2019) pmid: 31350521", "Include": "true"}, {"number": "186", "ReferenceId": "31257072", "FullCitation": "Fedoriw A, et al. Cancer Cell (2019) pmid: 31257072", "Include": "true"}, {"number": "187", "ReferenceId": "31287990", "FullCitation": "Srour N, et al. Cancer Cell (2019) pmid: 31287990", "Include": "true"}, {"number": "188", "ReferenceId": "30916320", "FullCitation": "Gao G, et al. Nucleic Acids Res. (2019) pmid: 30916320", "Include": "true"}, {"number": "189", "ReferenceId": "35041419", "FullCitation": "Smith CR, et al. J Med Chem (2022) pmid: 35041419", "Include": "true"}, {"number": "190", "ReferenceId": "31040154", "FullCitation": "Hansen LJ, et al. Cancer Res. (2019) pmid: 31040154", "Include": "true"}, {"number": "191", "ReferenceId": "29844120", "FullCitation": "Tang B, et al. Cancer Res. (2018) pmid: 29844120", "Include": "true"}, {"number": "192", "ReferenceId": "24928612", "FullCitation": "Munshi PN, et al. Oncologist (2014) pmid: 24928612", "Include": "true"}, {"number": "193", "ReferenceId": "26751376", "FullCitation": "de Oliveira SF, et al. PLoS ONE (2016) pmid: 26751376", "Include": "true"}, {"number": "194", "ReferenceId": "19478948", "FullCitation": "Lubin M, et al. PLoS ONE (2009) pmid: 19478948", "Include": "true"}, {"number": "195", "ReferenceId": "22825330", "FullCitation": "Tang B, et al. Cancer Biol. Ther. (2012) pmid: 22825330", "Include": "true"}, {"number": "196", "ReferenceId": "22252602", "FullCitation": "Collins CC, et al. Mol. Cancer Ther. (2012) pmid: 22252602", "Include": "true"}, {"number": "197", "ReferenceId": "21301207", "FullCitation": "Bertino JR, et al. Cancer Biol. Ther. (2011) pmid: 21301207", "Include": "true"}, {"number": "198", "ReferenceId": "21282358", "FullCitation": "Coulthard SA, et al. Mol. Cancer Ther. (2011) pmid: 21282358", "Include": "true"}, {"number": "199", "ReferenceId": "17912432", "FullCitation": "Miyazaki S, et al. Int. J. Oncol. (2007) pmid: 17912432", "Include": "true"}, {"number": "200", "ReferenceId": "11987241", "FullCitation": "Efferth T, et al. Blood Cells Mol. Dis. () pmid: 11987241", "Include": "true"}, {"number": "201", "ReferenceId": "18618081", "FullCitation": "Kindler HL, et al. Invest New Drugs (2009) pmid: 18618081", "Include": "true"}, {"number": "202", "ReferenceId": "35379845", "FullCitation": "Alhalabi O, et al. Nat Commun (2022) pmid: 35379845", "Include": "true"}, {"number": "203", "ReferenceId": "18094723", "FullCitation": "Welcker M, et al. Nat. Rev. Cancer (2008) pmid: 18094723", "Include": "true"}, {"number": "204", "ReferenceId": "17909001", "FullCitation": "Akhoondi S, et al. Cancer Res. (2007) pmid: 17909001", "Include": "true"}, {"number": "205", "ReferenceId": "24298052", "FullCitation": "Welcker M, et al. Genes Dev. (2013) pmid: 24298052", "Include": "true"}, {"number": "206", "ReferenceId": "17298674", "FullCitation": "Welcker M, et al. Cell Div (2007) pmid: 17298674", "Include": "true"}, {"number": "207", "ReferenceId": "11565034", "FullCitation": "Strohmaier H, et al. Nature (2001) pmid: 11565034", "Include": "true"}, {"number": "208", "ReferenceId": "21070969", "FullCitation": "Pashkova N, et al. Mol. Cell (2010) pmid: 21070969", "Include": "true"}, {"number": "209", "ReferenceId": "17646409", "FullCitation": "O Neil J, et al. J. Exp. Med. (2007) pmid: 17646409", "Include": "true"}, {"number": "210", "ReferenceId": "23228967", "FullCitation": "Malyukova A, et al. Leukemia (2013) pmid: 23228967", "Include": "true"}, {"number": "211", "ReferenceId": "17646408", "FullCitation": "Thompson BJ, et al. J. Exp. Med. (2007) pmid: 17646408", "Include": "true"}, {"number": "212", "ReferenceId": "17326833", "FullCitation": "Hagedorn M, et al. Cell Div (2007) pmid: 17326833", "Include": "true"}, {"number": "213", "ReferenceId": "18787170", "FullCitation": "Mao JH, et al. Science (2008) pmid: 18787170", "Include": "true"}, {"number": "214", "ReferenceId": "25749036", "FullCitation": "Yang H, et al. Oncotarget (2015) pmid: 25749036", "Include": "true"}, {"number": "215", "ReferenceId": "24360397", "FullCitation": "Villaruz LC, et al. Lung Cancer (2014) pmid: 24360397", "Include": "true"}, {"number": "216", "ReferenceId": "27079472", "FullCitation": "Olson D, et al. Clin Genitourin Cancer (2016) pmid: 27079472", "Include": "true"}, {"number": "217", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "218", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "219", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "220", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "221", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "222", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "223", "ReferenceId": "15331927", "FullCitation": "Martinez R, et al. Oncology (2004) pmid: 15331927", "Include": "true"}, {"number": "224", "ReferenceId": "15672285", "FullCitation": "Martinez R, et al. J. Cancer Res. Clin. Oncol. (2005) pmid: 15672285", "Include": "true"}, {"number": "225", "ReferenceId": "17498554", "FullCitation": "Martinez R, et al. Cancer Genet. Cytogenet. (2007) pmid: 17498554", "Include": "true"}, {"number": "226", "ReferenceId": "12908754", "FullCitation": "Szybka M, et al. Clin. Neuropathol. () pmid: 12908754", "Include": "true"}, {"number": "227", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "228", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "229", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "230", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "231", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "232", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "233", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "234", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "235", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "236", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "237", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "238", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "239", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "240", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "241", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "242", "ReferenceId": "32322066", "FullCitation": "Touat M, et al. Nature (2020) pmid: 32322066", "Include": "true"}, {"number": "243", "ReferenceId": "30742119", "FullCitation": "Zhao J, et al. Nat. Med. (2019) pmid: 30742119", "Include": "true"}, {"number": "244", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "245", "ReferenceId": "27001570", "FullCitation": "Bouffet E, et al. J. Clin. Oncol. (2016) pmid: 27001570", "Include": "true"}, {"number": "246", "ReferenceId": "27683556", "FullCitation": "Johanns TM, et al. Cancer Discov (2016) pmid: 27683556", "Include": "true"}, {"number": "247", "ReferenceId": "30073642", "FullCitation": "Lukas RV, et al. J. Neurooncol. (2018) pmid: 30073642", "Include": "true"}, {"number": "248", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "249", "ReferenceId": "32386112", "FullCitation": "Patel RR, et al. Pediatr Blood Cancer (2020) pmid: 32386112", "Include": "true"}, {"number": "250", "ReferenceId": "28912153", "FullCitation": "Johnson A, et al. Oncologist (2017) pmid: 28912153", "Include": "true"}, {"number": "251", "ReferenceId": "26699864", "FullCitation": "Draaisma K, et al. Acta Neuropathol Commun (2015) pmid: 26699864", "Include": "true"}, {"number": "252", "ReferenceId": "32164609", "FullCitation": "Wang L, et al. BMC Cancer (2020) pmid: 32164609", "Include": "true"}, {"number": "253", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "254", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "255", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "256", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "257", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "258", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "259", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "260", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "261", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "262", "ReferenceId": "8521522", "FullCitation": "Quelle DE, et al. Cell (1995) pmid: 8521522", "Include": "true"}, {"number": "263", "ReferenceId": "15878778", "FullCitation": "Mutat. Res. (2005) pmid: 15878778", "Include": "true"}, {"number": "264", "ReferenceId": "9484839", "FullCitation": "Gazzeri S, et al. Oncogene (1998) pmid: 9484839", "Include": "true"}, {"number": "265", "ReferenceId": "10498883", "FullCitation": "Oncogene (1999) pmid: 10498883", "Include": "true"}, {"number": "266", "ReferenceId": "16869746", "FullCitation": "Sherr CJ, et al. Cold Spring Harb. Symp. Quant. Biol. (2005) pmid: 16869746", "Include": "true"}, {"number": "267", "ReferenceId": "20549699", "FullCitation": "Ozenne P, et al. Int. J. Cancer (2010) pmid: 20549699", "Include": "true"}, {"number": "268", "ReferenceId": "10498896", "FullCitation": "Ruas M, et al. Oncogene (1999) pmid: 10498896", "Include": "true"}, {"number": "269", "ReferenceId": "17909018", "FullCitation": "Jones R, et al. Cancer Res. (2007) pmid: 17909018", "Include": "true"}, {"number": "270", "ReferenceId": "18843795", "FullCitation": "Haferkamp S, et al. Aging Cell (2008) pmid: 18843795", "Include": "true"}, {"number": "271", "ReferenceId": "12417717", "FullCitation": "Huot TJ, et al. Mol. Cell. Biol. (2002) pmid: 12417717", "Include": "true"}, {"number": "272", "ReferenceId": "11518711", "FullCitation": "Rizos H, et al. J. Biol. Chem. (2001) pmid: 11518711", "Include": "true"}, {"number": "273", "ReferenceId": "9324288", "FullCitation": "Gombart AF, et al. Leukemia (1997) pmid: 9324288", "Include": "true"}, {"number": "274", "ReferenceId": "7780957", "FullCitation": "Yang R, et al. Cancer Res. (1995) pmid: 7780957", "Include": "true"}, {"number": "275", "ReferenceId": "8668202", "FullCitation": "Parry D, et al. Mol. Cell. Biol. (1996) pmid: 8668202", "Include": "true"}, {"number": "276", "ReferenceId": "12606942", "FullCitation": "Greenblatt MS, et al. Oncogene (2003) pmid: 12606942", "Include": "true"}, {"number": "277", "ReferenceId": "10491434", "FullCitation": "Yarbrough WG, et al. J. Natl. Cancer Inst. (1999) pmid: 10491434", "Include": "true"}, {"number": "278", "ReferenceId": "11255261", "FullCitation": "Poi MJ, et al. Mol. Carcinog. (2001) pmid: 11255261", "Include": "true"}, {"number": "279", "ReferenceId": "9660926", "FullCitation": "Byeon IJ, et al. Mol. Cell (1998) pmid: 9660926", "Include": "true"}, {"number": "280", "ReferenceId": "19260062", "FullCitation": "Kannengiesser C, et al. Hum. Mutat. (2009) pmid: 19260062", "Include": "true"}, {"number": "281", "ReferenceId": "10719365", "FullCitation": "Lal G, et al. Genes Chromosomes Cancer (2000) pmid: 10719365", "Include": "true"}, {"number": "282", "ReferenceId": "7777061", "FullCitation": "Koh J, et al. Nature (1995) pmid: 7777061", "Include": "true"}, {"number": "283", "ReferenceId": "20340136", "FullCitation": "McKenzie HA, et al. Hum. Mutat. (2010) pmid: 20340136", "Include": "true"}, {"number": "284", "ReferenceId": "21462282", "FullCitation": "Miller PJ, et al. Hum. Mutat. (2011) pmid: 21462282", "Include": "true"}, {"number": "285", "ReferenceId": "905385", "FullCitation": "Kutscher CL, et al. Physiol. Behav. (1977) pmid: 905385", "Include": "true"}, {"number": "286", "ReferenceId": "24659262", "FullCitation": "Scaini MC, et al. Hum. Mutat. (2014) pmid: 24659262", "Include": "true"}, {"number": "287", "ReferenceId": "23190892", "FullCitation": "Jenkins NC, et al. J. Invest. Dermatol. (2013) pmid: 23190892", "Include": "true"}, {"number": "288", "ReferenceId": "10389768", "FullCitation": "Walker GJ, et al. Int. J. Cancer (1999) pmid: 10389768", "Include": "true"}, {"number": "289", "ReferenceId": "12853981", "FullCitation": "Rutter JL, et al. Oncogene (2003) pmid: 12853981", "Include": "true"}, {"number": "290", "ReferenceId": "18538737", "FullCitation": "Itahana K, et al. Cancer Cell (2008) pmid: 18538737", "Include": "true"}, {"number": "291", "ReferenceId": "10360174", "FullCitation": "Zhang Y, et al. Mol. Cell (1999) pmid: 10360174", "Include": "true"}, {"number": "292", "ReferenceId": "9529249", "FullCitation": "Zhang Y, et al. Cell (1998) pmid: 9529249", "Include": "true"}, {"number": "293", "ReferenceId": "25873077", "FullCitation": "Jafri M, et al. Cancer Discov (2015) pmid: 25873077", "Include": "true"}, {"number": "294", "ReferenceId": "26824661", "FullCitation": "Ceccarelli M, et al. Cell (2016) pmid: 26824661", "Include": "true"}, {"number": "295", "ReferenceId": "31263031", "FullCitation": "Jonsson P, et al. Clin. Cancer Res. (2019) pmid: 31263031", "Include": "true"}, {"number": "296", "ReferenceId": "20129251", "FullCitation": "Verhaak RG, et al. Cancer Cell (2010) pmid: 20129251", "Include": "true"}, {"number": "297", "ReferenceId": "16909113", "FullCitation": "Weber RG, et al. Oncogene (2007) pmid: 16909113", "Include": "true"}, {"number": "298", "ReferenceId": "11303791", "FullCitation": "Nakamura M, et al. Brain Pathol. (2001) pmid: 11303791", "Include": "true"}, {"number": "299", "ReferenceId": "11489817", "FullCitation": "Chakravarti A, et al. Clin. Cancer Res. (2001) pmid: 11489817", "Include": "true"}, {"number": "300", "ReferenceId": "21713760", "FullCitation": "Feng J, et al. Cancer (2012) pmid: 21713760", "Include": "true"}, {"number": "301", "ReferenceId": "21636552", "FullCitation": "Raabe EH, et al. Clin. Cancer Res. (2011) pmid: 21636552", "Include": "true"}, {"number": "302", "ReferenceId": "21843312", "FullCitation": "Liu W, et al. J. Exp. Clin. Cancer Res. (2011) pmid: 21843312", "Include": "true"}, {"number": "303", "ReferenceId": "21278246", "FullCitation": "Konecny GE, et al. Clin. Cancer Res. (2011) pmid: 21278246", "Include": "true"}, {"number": "304", "ReferenceId": "21871868", "FullCitation": "Katsumi Y, et al. Biochem. Biophys. Res. Commun. (2011) pmid: 21871868", "Include": "true"}, {"number": "305", "ReferenceId": "22711607", "FullCitation": "Cen L, et al. Neuro_oncology (2012) pmid: 22711607", "Include": "true"}, {"number": "306", "ReferenceId": "23898052", "FullCitation": "Logan JE, et al. Anticancer Res. (2013) pmid: 23898052", "Include": "true"}, {"number": "307", "ReferenceId": "35157829", "FullCitation": "Fennell DA, et al. Lancet Oncol (2022) pmid: 35157829", "Include": "true"}, {"number": "308", "ReferenceId": "28283584", "FullCitation": "Elvin JA, et al. Oncologist (2017) pmid: 28283584", "Include": "true"}, {"number": "309", "ReferenceId": "26715889", "FullCitation": "Gao J, et al. Curr Oncol (2015) pmid: 26715889", "Include": "true"}, {"number": "310", "ReferenceId": "25501126", "FullCitation": "DeMichele A, et al. Clin. Cancer Res. (2015) pmid: 25501126", "Include": "true"}, {"number": "311", "ReferenceId": "25524798", "FullCitation": "Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798", "Include": "true"}, {"number": "312", "ReferenceId": "27542767", "FullCitation": "Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767", "Include": "true"}, {"number": "313", "ReferenceId": "24797823", "FullCitation": "Johnson DB, et al. Oncologist (2014) pmid: 24797823", "Include": "true"}, {"number": "314", "ReferenceId": "21460101", "FullCitation": "Van Maerken T, et al. Mol. Cancer Ther. (2011) pmid: 21460101", "Include": "true"}, {"number": "315", "ReferenceId": "21725357", "FullCitation": "Gamble LD, et al. Oncogene (2012) pmid: 21725357", "Include": "true"}, {"number": "316", "ReferenceId": "22090362", "FullCitation": "Flaherty KT, et al. Clin. Cancer Res. (2012) pmid: 22090362", "Include": "true"}, {"number": "317", "ReferenceId": "23569312", "FullCitation": "Dickson MA, et al. J. Clin. Oncol. (2013) pmid: 23569312", "Include": "true"}, {"number": "318", "ReferenceId": "7666917", "FullCitation": "Whelan AJ, et al. N Engl J Med (1995) pmid: 7666917", "Include": "true"}, {"number": "319", "ReferenceId": "20687502", "FullCitation": "Adv Exp Med Biol (2010) pmid: 20687502", "Include": "true"}, {"number": "320", "ReferenceId": "9479083", "FullCitation": "Hogg D, et al. J Cutan Med Surg (1998) pmid: 9479083", "Include": "true"}, {"number": "321", "ReferenceId": "29543703", "FullCitation": "De Unamuno B, et al. Melanoma Res (2018) pmid: 29543703", "Include": "true"}, {"number": "322", "ReferenceId": "26892650", "FullCitation": "Soura E, et al. J Am Acad Dermatol (2016) pmid: 26892650", "Include": "true"}, {"number": "323", "ReferenceId": "29405243", "FullCitation": "Huerta C, et al. Acta Derm Venereol (2018) pmid: 29405243", "Include": "true"}, {"number": "324", "ReferenceId": "8414022", "FullCitation": "Kaufman DK, et al. Neurology (1993) pmid: 8414022", "Include": "true"}, {"number": "325", "ReferenceId": "9622062", "FullCitation": "Bahuau M, et al. Cancer Res (1998) pmid: 9622062", "Include": "true"}, {"number": "326", "ReferenceId": "28699883", "FullCitation": "Chan AK, et al. Clin Neuropathol () pmid: 28699883", "Include": "true"}, {"number": "327", "ReferenceId": "22015685", "FullCitation": "Shay JW, et al. Semin. Cancer Biol. (2011) pmid: 22015685", "Include": "true"}, {"number": "328", "ReferenceId": "9282118", "FullCitation": "Shay JW, et al. Eur. J. Cancer (1997) pmid: 9282118", "Include": "true"}, {"number": "329", "ReferenceId": "7605428", "FullCitation": "Kim NW, et al. Science (1994) pmid: 7605428", "Include": "true"}, {"number": "330", "ReferenceId": "10647931", "FullCitation": "Hanahan D, et al. Cell (2000) pmid: 10647931", "Include": "true"}, {"number": "331", "ReferenceId": "23348503", "FullCitation": "Horn S, et al. Science (2013) pmid: 23348503", "Include": "true"}, {"number": "332", "ReferenceId": "23348506", "FullCitation": "Huang FW, et al. Science (2013) pmid: 23348506", "Include": "true"}, {"number": "333", "ReferenceId": "23887589", "FullCitation": "Vinagre J, et al. Nat Commun (2013) pmid: 23887589", "Include": "true"}, {"number": "334", "ReferenceId": "23530248", "FullCitation": "Killela PJ, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 23530248", "Include": "true"}, {"number": "335", "ReferenceId": "24722048", "FullCitation": "Killela PJ, et al. Oncotarget (2014) pmid: 24722048", "Include": "true"}, {"number": "336", "ReferenceId": "23955565", "FullCitation": "Nonoguchi N, et al. Acta Neuropathol. (2013) pmid: 23955565", "Include": "true"}, {"number": "337", "ReferenceId": "23603989", "FullCitation": "Liu X, et al. Cell Cycle (2013) pmid: 23603989", "Include": "true"}, {"number": "338", "ReferenceId": "24154961", "FullCitation": "Koelsche C, et al. Acta Neuropathol. (2013) pmid: 24154961", "Include": "true"}, {"number": "339", "ReferenceId": "23764841", "FullCitation": "Arita H, et al. Acta Neuropathol. (2013) pmid: 23764841", "Include": "true"}, {"number": "340", "ReferenceId": "24217890", "FullCitation": "Reitman ZJ, et al. Acta Neuropathol. (2013) pmid: 24217890", "Include": "true"}, {"number": "341", "ReferenceId": "27245281", "FullCitation": "Nat Rev Clin Oncol (2017) pmid: 27245281", "Include": "true"}, {"number": "342", "ReferenceId": "29249395", "FullCitation": "Duperret EK, et al. Mol Ther (2018) pmid: 29249395", "Include": "true"}, {"number": "343", "ReferenceId": "25467017", "FullCitation": "Chiappori AA, et al. Ann Oncol (2015) pmid: 25467017", "Include": "true"}, {"number": "344", "ReferenceId": "33293629", "FullCitation": "Weller M, et al. Nat Rev Clin Oncol (2021) pmid: 33293629", "Include": "true"}, {"number": "345", "ReferenceId": "34185076", "FullCitation": "Louis DN, et al. Neuro Oncol (2021) pmid: 34185076", "Include": "true"}, {"number": "346", "ReferenceId": "23898124", "FullCitation": "Zustovich F, et al. Anticancer Res. (2013) pmid: 23898124", "Include": "true"}, {"number": "347", "ReferenceId": "20443129", "FullCitation": "Reardon DA, et al. J. Neurooncol. (2011) pmid: 20443129", "Include": "true"}, {"number": "348", "ReferenceId": "23099651", "FullCitation": "Lee EQ, et al. Neuro_oncology (2012) pmid: 23099651", "Include": "true"}, {"number": "349", "ReferenceId": "23328813", "FullCitation": "Peereboom DM, et al. Neuro_oncology (2013) pmid: 23328813", "Include": "true"}, {"number": "350", "ReferenceId": "24786603", "FullCitation": "Hottinger AF, et al. Br. J. Cancer (2014) pmid: 24786603", "Include": "true"}, {"number": "351", "ReferenceId": "24803676", "FullCitation": "Karajannis MA, et al. Neuro_oncology (2014) pmid: 24803676", "Include": "true"}, {"number": "352", "ReferenceId": "29710216", "FullCitation": "Schuetze SM, et al. JAMA Oncol (2018) pmid: 29710216", "Include": "true"}, {"number": "353", "ReferenceId": "25674429", "FullCitation": "Hassler MR, et al. Springerplus (2014) pmid: 25674429", "Include": "true"}, {"number": "354", "ReferenceId": "19789313", "FullCitation": "Razis E, et al. Clin. Cancer Res. (2009) pmid: 19789313", "Include": "true"}, {"number": "355", "ReferenceId": "19904263", "FullCitation": "Reardon DA, et al. Br. J. Cancer (2009) pmid: 19904263", "Include": "true"}, {"number": "356", "ReferenceId": "22371319", "FullCitation": "Reardon DA, et al. Cancer (2012) pmid: 22371319", "Include": "true"}, {"number": "357", "ReferenceId": "17377585", "FullCitation": "Metzgeroth G, et al. Leukemia (2007) pmid: 17377585", "Include": "true"}, {"number": "358", "ReferenceId": "20921209", "FullCitation": "Sarkaria JN, et al. Clin. Cancer Res. (2010) pmid: 20921209", "Include": "true"}, {"number": "359", "ReferenceId": "23564811", "FullCitation": "Lassen U, et al. Anticancer Res. (2013) pmid: 23564811", "Include": "true"}, {"number": "360", "ReferenceId": "22033322", "FullCitation": "Geoerger B, et al. Eur. J. Cancer (2012) pmid: 22033322", "Include": "true"}, {"number": "361", "ReferenceId": "24470557", "FullCitation": "Wen PY, et al. Neuro_oncology (2014) pmid: 24470557", "Include": "true"}, {"number": "362", "ReferenceId": "25344362", "FullCitation": "Tolcher AW, et al. Ann. Oncol. (2015) pmid: 25344362", "Include": "true"}, {"number": "363", "ReferenceId": "22706484", "FullCitation": "Hainsworth JD, et al. Clin Adv Hematol Oncol (2012) pmid: 22706484", "Include": "true"}, {"number": "364", "ReferenceId": "25526733", "FullCitation": "Ma DJ, et al. Neuro_oncology (2015) pmid: 25526733", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2022_09_16 01:08:50", "OpName": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "806x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "1 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "BRAIN", "disease_ontology": "Brain glioblastoma (GBM)", "flowcell_analysis": "2000023529", "gender": "male", "pathology_diagnosis": "Glioblastoma", "percent_tumor_nuclei": "50", "pipeline_version": "v3.14.0", "purity_assessment": "53.7", "specimen": "ORD_1450680_01*US1390545.01", "study": "CLINICAL_F1CDx v2", "test_request": "ORD_1450680_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Brain", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX2", "mean_exon_depth": "815.33", "name": "SQ_US1390545.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.2388", "cds_effect": "_124C>T", "depth": "201", "equivocal": "false", "functional_effect": "promoter", "gene": "TERT", "percent_reads": "23.88", "position": "chr5:1295228", "protein_effect": "promoter _124C>T", "status": "known", "strand": "_", "transcript": "NM_198253", "dna_evidence": {"sample": "SQ_US1390545.01_1"}}, {"allele_fraction": "0.2491", "cds_effect": "1394G>A", "depth": "831", "equivocal": "false", "functional_effect": "missense", "gene": "FBXW7", "percent_reads": "24.91", "position": "chr4:153249384", "protein_effect": "R465H", "status": "known", "strand": "_", "transcript": "NM_033632", "dna_evidence": {"sample": "SQ_US1390545.01_1"}}, {"allele_fraction": "0.009", "cds_effect": "2525A>T", "depth": "1786", "equivocal": "false", "functional_effect": "missense", "gene": "PDGFRA", "percent_reads": "0.9", "position": "chr4:55152093", "protein_effect": "D842V", "status": "known", "strand": "+", "subclonal": "true", "transcript": "NM_006206", "dna_evidence": {"sample": "SQ_US1390545.01_1"}}, {"allele_fraction": "0.2558", "cds_effect": "3185G>A", "depth": "864", "equivocal": "false", "functional_effect": "missense", "gene": "TSC1", "percent_reads": "25.58", "position": "chr9:135771932", "protein_effect": "R1062Q", "status": "unknown", "strand": "_", "transcript": "NM_000368", "dna_evidence": {"sample": "SQ_US1390545.01_1"}}, {"allele_fraction": "0.4728", "cds_effect": "1541T>C", "depth": "681", "equivocal": "false", "functional_effect": "missense", "gene": "MERTK", "percent_reads": "47.28", "position": "chr2:112754990", "protein_effect": "L514S", "status": "unknown", "strand": "+", "transcript": "NM_006343", "dna_evidence": {"sample": "SQ_US1390545.01_1"}}, {"allele_fraction": "0.3799", "cds_effect": "38T>C", "depth": "787", "equivocal": "false", "functional_effect": "missense", "gene": "MITF", "percent_reads": "37.99", "position": "chr3:69788786", "protein_effect": "V13A", "status": "unknown", "strand": "+", "transcript": "NM_198159", "dna_evidence": {"sample": "SQ_US1390545.01_1"}}, {"allele_fraction": "0.4963", "cds_effect": "808G>T", "depth": "675", "equivocal": "false", "functional_effect": "missense", "gene": "ERBB2", "percent_reads": "49.63", "position": "chr17:37866641", "protein_effect": "A270S", "status": "unknown", "strand": "+", "transcript": "NM_004448", "dna_evidence": {"sample": "SQ_US1390545.01_1"}}, {"allele_fraction": "0.5379", "cds_effect": "1026G>C", "depth": "647", "equivocal": "false", "functional_effect": "missense", "gene": "PTEN", "percent_reads": "53.79", "position": "chr10:89720875", "protein_effect": "K342N", "status": "known", "strand": "+", "transcript": "NM_000314", "dna_evidence": {"sample": "SQ_US1390545.01_1"}}]}, "copy_number_alterations": {"copy_number_alteration": [{"copy_number": "0", "equivocal": "false", "gene": "MTAP", "number_of_exons": "8 of 8", "position": "chr9:21802699_21862058", "ratio": "0.5", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1390545.01_1"}}, {"copy_number": "0", "equivocal": "false", "gene": "CDKN2A", "number_of_exons": "5 of 5", "position": "chr9:21853212_21998002", "ratio": "0.49", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1390545.01_1"}}, {"copy_number": "0", "equivocal": "false", "gene": "CDKN2B", "number_of_exons": "5 of 5", "position": "chr9:21998748_22101832", "ratio": "0.5", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1390545.01_1"}}]}, "rearrangements": {"rearrangement": {"description": "PDGFRA(NM_006206) deletion intron 7 _ exon 9", "equivocal": "false", "in_frame": "unknown", "other_gene": "PDGFRA", "pos1": "chr4:55136026_55136447", "pos2": "chr4:55138571_55138778", "status": "known", "supporting_read_pairs": "9", "targeted_gene": "PDGFRA", "type": "deletion", "dna_evidence": {"sample": "SQ_US1390545.01_1"}}}, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "1.21", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}